WEST Search History

Hide Items | Restore | Clear | Cancel

DATE: Thursday, April 28, 2005

Hide?	Set Name	Query	Hit Count
		DB=PGPB,USPT,USOC; THES=ASSIGNEE; PLUR=YES; OP=ADJ	
☐	L4	L3 and cleav$3 (site|motif|sequence)	65
☐	L3	L2 and $4peptide?	82
☐	L2	L1 and cleav$3	84
☐	L1	(hk2 | hGK1 |human kallikrein 2) and proteoly$4 and pharmaceutical composition	84

END OF SEARCH HISTORY

Hit List

Clear | Generate Collection | Print | Fwd Refs | Bkwd Refs | Generate OACS

Search Results - Record(s) 1 through 65 of 65 returned.

☐ 1. Document ID: US 20050054835 A1

Using default format because multiple data bases are involved.

L4: Entry 1 of 65 File: PGPB Mar 10, 2005

PGPUB-DOCUMENT-NUMBER: 20050054835
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20050054835 A1

TITLE: Immunotoxins comprising ribosome-inactivating proteins

PUBLICATION-DATE: March 10, 2005

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Better, Marc D.	Los Angeles	CA	US	
Carroll, Stephen F.	Walnut Creek	CA	US	
Studnicka, Gary M.	Santa Monica	CA	US	

US-CL-CURRENT: 530/391.1; 435/320.1, 435/328, 435/69.7, 536/23.53

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | Claims | KWIC | Draw De

☐ 2. Document ID: US 20050003453 A1

L4: Entry 2 of 65 File: PGPB Jan 6, 2005

PGPUB-DOCUMENT-NUMBER: 20050003453
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20050003453 A1

TITLE: G-CSF analog compositions and methods

PUBLICATION-DATE: January 6, 2005

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Sarkar, Casim A.	Cambridge	MA	US	
Lauffenburger, Douglas A.	Cambridge	MA	US	

US-CL-CURRENT: 435/7.1; 530/351, 702/19

ABSTRACT:

The present invention relates to granulocyte colony stimulating factor ("G-CSF") polypeptide analog compositions. The concept detailed herein provides methods for screening G-CSF analogs, designed with one or more substitutions to amino acids, and selecting analogs for use as G-CSF replacements or antagonists, and may be generalizable beyond G-CSF analogs as well. In addition, pharmaceutical compositions and methods of use are provided for analogs so selected.

☐ 3. Document ID: US 20040265798 A1

L4: Entry 3 of 65 File: PGPB Dec 30, 2004

PGPUB-DOCUMENT-NUMBER: 20040265798
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20040265798 A1

TITLE: Methods and compositions related to high-titer pseudotyped retroviruses

PUBLICATION-DATE: December 30, 2004

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
McCray, Paul	Iowa City	IA	US	
Fan, Hung	Laguna Beach	CA	US	
Sinn, Patrick	Iowa City	IA	US	

US-CL-CURRENT: 435/5; 435/235.1, 536/23.72

ABSTRACT:

The present invention concerns the methods and compositions related to pseudotyped viral vectors. Embodiments of the invention include pseudotyping expression cassettes that include nucleic acid elements for enhancing the titer of pseudotyped viral particles. Embodiments of the invention include novel methods and compositions related to making high titer pseudotyped retroviral vector compositions. A heterologous envelope glycoprotein is typically incorporated into the virus during the budding or virus production process. Certain embodiments of the invention include pseudotyped retroviral vectors comprising a heterologous envelope glycoprotein derived from a Jaagsiekte sheep retrovirus (JSRV env). Pseudotyped viruses or viral particles may have a modified host range that is influenced by the properties of the heterologous envelope glycoprotein. Thus, embodiments of the invention include improved methods and compositions related to pseudotyped viruses suitable for ex vivo and in vivo methods including gene transfer and other therapeutic and experimental methods.

☐ 4. Document ID: US 20040235095 A1

L4: Entry 4 of 65 File: PGPB Nov 25, 2004

PGPUB-DOCUMENT-NUMBER: 20040235095
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20040235095 A1

TITLE: Proaerolysin containing protease activation sequences and methods of use for treatment of prostate cancer

PUBLICATION-DATE: November 25, 2004

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Denmeade, Samuel R.	Ellicot City	MD	US	
Isaacs, John T.	Phoenix	MD	US	
Buckley, James Thomas	Victoria		CA	

US-CL-CURRENT: 435/69.1; 435/226, 435/320.1, 435/325, 530/350, 536/23.2

ABSTRACT:

Disclosed herein are modified proaerolysin (PA) peptide. In some examples, the proteins include a prostate-specific protease cleavage site and can further include a prostate-tissue-specific binding domain which functionally replaces the native PA binding domain. In other examples, the proteins include a furin cleavage site and a prostate tissue-specific binding domain which functionally replaces the native PA binding domain. Methods of using such peptides to treat prostate cancer are also disclosed.

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | Claims | KWIC | Draw De

---

☐ 5. Document ID: US 20040235071 A1

L4: Entry 5 of 65 File: PGPB Nov 25, 2004

PGPUB-DOCUMENT-NUMBER: 20040235071
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20040235071 A1

TITLE: Methods and compositions for treating cancer using 15986, 2188, 20743, 9148, 9151, 9791, 44252, 14184, 42461, 8204, 7970, 25552, 21657, 26492, 2411, 15088, 1905, 28899, 63380, 33935, 10480, 12686, 25501, 17694, 15701, 53062, 49908, 21612, 38949, 6216, 46863, 9235, 2201, 6985, 9883, 12238, 18057, 21617, 39228, 49928, 54476, 62113, 64316, 12264, 32362, 58198, 2887, 3205, 8557, 9600, 9693, 44867, 53058, 55556, 57658, 2208, 10252, 10302, 14218, 33877, 10317, 10485, 25964, 14815, 1363, 1397, 14827, 21708, 3801, 64698, 2179 or 13249

PUBLICATION-DATE: November 25, 2004

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Lightcap, Eric S.	Natick	MA	US	
Ecsedy, Jeffrey A.	Jamaica Plain	MA	US	
Hunter, John J.	Oakland	CA	US	
MacBeth, Kyle J.	Boston	MA	US	
Nestor, Michelle Tighe	North Woodstock	NH	US	

US-CL-CURRENT: 435/7.23

ABSTRACT:

The present invention relates to methods for the diagnosis and treatment of a cancer or cancer. Specifically, the present invention identifies the differential expression of 15986, 2188, 20743, 9148, 9151, 9791, 44252, 14184, 42461, 8204, 7970, 25552, 21657, 26492, 2411, 15088, 1905, 28899, 63380, 33935, 10480, 12686, 25501, 17694, 15701, 53062, 49908, 21612, 38949, 6216, 46863, 9235, 2201, 6985, 9883, 12238, 18057, 21617, 39228, 49928, 54476, 62113, 64316, 12264, 32362, 58198, 2887, 3205, 8557, 9600, 9693, 44867, 53058, 55556, 57658, 2208, 10252, 10302, 14218, 33877, 10317, 10485, 25964, 14815, 1363, 1397, 14827, 21708, 3801, 64698, 2179 and 13249 genes in tissues relating to cancer, relative to their expression in normal, or non-cancer disease states, and/or in response to manipulations relevant to a cancer. The present invention describes methods for the diagnostic evaluation and prognosis of various cancers, and for the identification of subjects exhibiting a predisposition to such conditions. The invention also provides methods for identifying a compound capable of modulating a cancer or cancer. The present invention also provides methods for the identification and therapeutic use of compounds as treatments of cancer.

☐ 6. Document ID: US 20040230380 A1

L4: Entry 6 of 65 File: PGPB Nov 18, 2004

PGPUB-DOCUMENT-NUMBER: 20040230380
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20040230380 A1

TITLE: Novel proteins with altered immunogenicity

PUBLICATION-DATE: November 18, 2004

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Chirino, Arthur J.	Camarillo	CA	US	
Dahiyat, Bassil I.	Altadena	CA	US	
Desjarlais, John Rudolph	Pasadena	CA	US	
Marshall, Shannon Alicia	San Francisco	CA	US	

US-CL-CURRENT: 702/19

ABSTRACT:

The present invention provides methods for combining computational methods for modulating protein immunogenicity with computational methods for identifying sequences with desired structural and functional properties. More specifically, the methods of the present invention may be used to identify modifications that increase or decrease the immunogenicity of a protein by affecting antigen uptake, MHC binding, T-cell binding, or antibody binding, while retaining or enhancing functional properties.

☐ 7. Document ID: US 20040224408 A1

L4: Entry 7 of 65 File: PGPB Nov 11, 2004

PGPUB-DOCUMENT-NUMBER: 20040224408
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20040224408 A1

TITLE: THAP proteins as nuclear receptors for chemokines and roles in transcriptional regulation, cell proliferation and cell differentiation

PUBLICATION-DATE: November 11, 2004

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Girard, Jean-Philippe	Rebigue		FR	
Amalric, Francois	Toulouse		FR	
Roussigne, Myriam	La Bastide sur L'Hers		FR	
Clouaire, Thomas	Toulouse		FR	

US-CL-CURRENT: 435/455; 514/44

ABSTRACT:

The invention relates to genes and proteins of the THAP family comprising a THAP domain, and their use in diagnostics, treatment of disease, and in the identification of molecules for the treatment of disease. The invention also relates to uses of THAP-type chemokine-binding agents, such as THAP-family proteins, as a nuclear receptors for a chemokines and to methods for the modulation (stimulation or inhibition) of transcription, cell proliferation and cell differentiation as well as methods for identifying for compounds which modulate THAP-chemokine interactions.

☐ 8. Document ID: US 20040197770 A1

L4: Entry 8 of 65 File: PGPB Oct 7, 2004

PGPUB-DOCUMENT-NUMBER: 20040197770
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20040197770 A1

TITLE: Induction of apoptosis by HIV-1 infected monocytic cells

PUBLICATION-DATE: October 7, 2004

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Sperber, Kirk	Bronxville	NY	US	
Gelman, Irwin H.	Buffalo	NY	US	

US-CL-CURRENT: 435/5

ABSTRACT:

The present invention generally relates to the treatment or inhibition of diseases associated with HIV-1 infection. In particular, the present invention identifies a protein, which is secreted by macrophages as a result of HIV infection. The secreted protein induces apoptosis in neuronal cells, as well as T cells and B cell. The protein is specifically expressed in the neuronal tissue of HAD patients but not in the neuronal tissue of patients with non-HIV associated dementia. Methods and compositions for decreasing, inhibiting, or otherwise abrogating neuronal cell apoptosis that leads to HIV-1 associated dementia are described.

☐ 9. Document ID: US 20040137455 A1

L4: Entry 9 of 65 File: PGPB Jul 15, 2004

PGPUB-DOCUMENT-NUMBER: 20040137455
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20040137455 A1

TITLE: Diagnosis of cancer or benign tumor using the aberrant expression product of the klk4 gene

PUBLICATION-DATE: July 15, 2004

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Dong, Ying	Queensland		AU	
Clements, Judith Ann	Queensland		AU	

US-CL-CURRENT: 435/6; 435/7.23

ABSTRACT:

The present invention discloses aberrant expression products of the KLK4 gene, which segregate with at least one condition selected from a cancer or a benign tumour. The invention also discloses a method for detecting the presence or diagnosing the risk of said at least one condition by detecting aberrant KLK4 expression The invention also discloses isolated polynucleotides comprising a nucleotide sequence that corresponds or is complementary to at least a portion of an aberrant KLK4 polynucleotide, which correlates with the presence or risk of said at least one condition. Also disclosed are isolated polypeptides comprising an amino acid sequence that corresponds to at least a portion of an aberrant K4 polypeptide, which correlates with the presence or risk of said at least one condition. The invention also extends to variants and derivatives of these molecules, to vectors comprising aberrant KLK4 polynucleotides and to host cells containing such vectors. The invention further extends to antigen-binding molecules that are immuno-interactive with aberrant K4 polypeptides and to the use of these antigen-binding molecules, the aberrant KLK4 polynucleotides and aberrant K4 polypeptides in assays and kits for detecting the presence or diagnosing the risk of said at least one condition. The invention further encompasses the use of functional KLK4 polynucleotides or functional K4 polypeptides or agents that modulate the level and/or functional activity of an expression product of KLK4 or of a gene belonging to the same biosynthetic or regulatory pathway as KLK4 for treating and/or preventing one or more of said conditions.

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | Claims | KWIC | Draw De

---

☐ 10. Document ID: US 20040110675 A1

L4: Entry 10 of 65 File: PGPB Jun 10, 2004

PGPUB-DOCUMENT-NUMBER: 20040110675
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20040110675 A1

TITLE: Mutant human factor ix with an increased resistance to inhibition by heparin

PUBLICATION-DATE: June 10, 2004

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Sheehan, John P.	Middleton	WI	US	

US-CL-CURRENT: 514/12; 530/383

ABSTRACT:

The present invention is related to a novel composition of matter and methods of using the same. More particularly, the invention describes mutant human factor IX which has an increased resistance to inhibition by heparin. Methods of making and using this composition for the therapeutic intervention of hemophilia are disclosed.

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | Claims | KWIC | Draw De

---

☐ 11. Document ID: US 20040106557 A1

L4: Entry 11 of 65 File: PGPB Jun 3, 2004

PGPUB-DOCUMENT-NUMBER: 20040106557
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20040106557 A1

TITLE: Peptide ligands for prostate specific antigen

PUBLICATION-DATE: June 3, 2004

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Ulf-Hakan, Stenman	Kauniainen		FI	
Koivunen, Erkki	Helsinki		FI	
Leinonen, Jari	Helsinki		FI	
Narvanen, Ale	Kuopio		FI	

US-CL-CURRENT: 514/15; 530/327

ABSTRACT:

The present invention relates to novel peptide ligands for prostate specific antigen (PSA) binding specifically with it and enhancing its enzyme activity, to a process for preparation of these peptides, to diagnostic and pharmaceutical compositions comprising these peptides, to the use of these peptides for pharmaceutical and research preparations, to methods using these peptides in diagnostic assays for determination of the concentrations of various molecular forms of PSA, to methods for modulating the PSA enzyme activity and PSA activity dependent conditions by using these peptides either in vivo or in vitro and to the use of these peptides in procedures for biochemical isolation and purification of PSA.

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | Claims | KWMC | Draw De

---

☐ 12. Document ID: US 20040058342 A1

L4: Entry 12 of 65 File: PGPB Mar 25, 2004

PGPUB-DOCUMENT-NUMBER: 20040058342
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20040058342 A1

TITLE: Novel kallikrein gene

PUBLICATION-DATE: March 25, 2004

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Yousef, George M	Toronto		CA	
Diamandis, Eleftherios P	Toronto		CA	

US-CL-CURRENT: 435/6; 435/226, 435/320.1, 435/325, 435/69.1, 530/388.26, 536/23.2

ABSTRACT:

The invention relates to nucleic acid molecules. proteins encoded by such nucleic acid molecules: and use of the proteins and nucleic acid molecule.

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | Claims | KWIC | Draw De

---

☐ 13. Document ID: US 20040033509 A1

L4: Entry 13 of 65 File: PGPB Feb 19, 2004

PGPUB-DOCUMENT-NUMBER: 20040033509
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20040033509 A1

TITLE: Novel 13237, 18480, 2245, 16228, 7677, 26320, 46619, 33166, 16836, 46867, 21617, 55562, 39228, 62088, 46745, 23155, 21657, 42755, 32229, 22325, 46863 and 32252 molecules and uses therefor

PUBLICATION-DATE: February 19, 2004

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Meyers, Rachel E.	Newton	MA	US	
Williamson, Mark J.	Saugus	MA	US	
Kapeller-Libermann, Rosana	Chestnut Hill	MA	US	
MacBeth, Kyle J.	Boston	MA	US	
Hunter, John Joseph	Somerville	MA	US	
Rudolph-Owen, Laura A.	Medford	MA	US	
Bandaru, Rajasekhar	Watertown	MA	US	
Tsai, Fong-Ying	Newton	MA	US	

US-CL-CURRENT: 435/6; 435/320.1, 435/325, 435/69.1, 530/350, 536/23.5

ABSTRACT:

The invention provides isolated nucleic acids molecules, designated 13237, 18480, 2245, 16228, 7677, 26320, 46619, 33166, 16836, 46867, 21617, 55562, 39228, 62088, 46745, 23155, 21657, 42755, 32229, 22325, 46863 and 32252 nucleic acid molecules. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing 13237, 18480, 2245, 16228, 7677, 26320, 46619, 33166, 16836, 46867, 21617, 55562, 39228, 62088, 46745, 23155, 21657, 42755, 32229, 22325, 46863 and 32252 nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a 13237, 18480, 2245, 16228, 7677, 26320, 46619, 33166, 16836, 46867, 21617, 55562, 39228, 62088, 46745, 23155, 21657, 42755, 32229, 22325, 46863 or 32252 gene has been introduced or disrupted. The invention still further provides isolated 13237, 18480, 2245, 16228, 7677, 26320, 46619, 33166, 16836, 46867, 21617, 55562, 39228, 62088, 46745, 23155, 21657, 42755, 32229, 22325, 46863 or 32252 proteins, fusion proteins, antigenic peptides and anti-13237, 18480, 2245, 16228, 7677, 26320,

46619, 33166, 16836, 46867, 21617, 55562, 39228, 62088, 46745, 23155, 21657, 42755, 32229, 22325, 46863 or 32252 antibodies. Diagnostic and therapeutic methods utilizing compositions of the invention are also provided.

☐ 14. Document ID: US 20040009553 A1

L4: Entry 14 of 65 File: PGPB Jan 15, 2004

PGPUB-DOCUMENT-NUMBER: 20040009553
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20040009553 A1

TITLE: Novel 27411, 23413, 22438, 23553, 25278, 26212, NARC SC1, NARC 10A, NARC 1, NARC 12, NARC 13, NARC17, NARC 25, NARC 3, NARC 4, NARC 7, NARC 8, NARC 11, NARC 14A, NARC 15, NARC 16, NARC 19, NARC 20, NARC 26, NARC 27, NARC 28, NARC 30, NARC 5, NARC 6, NARC 9, NARC 10C, NARC 8B, NARC 9, NARC2A, NARC 16B, NARC 1C, NARC1A, NARC 25, 86604 and 32222 molecules and uses therefor

PUBLICATION-DATE: January 15, 2004

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Glucksmann, Maria A.	Lexington	MA	US	
Williamson, Mark J.	Saugus	MA	US	
Tsai, Fong-Ying	Newton	MA	US	
Rudolph-Owen, Laura A.	Medford	MA	US	
Kapeller-Libermann, Rosanna	Chestnut Hill	MA	US	
Meyers, Rachel E.	Newton	MA	US	
Chiang, Lillian Wei-Ming	Edison	NJ	US	
Hunter, John Joseph	Somerville	MA	US	

US-CL-CURRENT: 435/69.1; 435/320.1, 435/325, 530/350, 536/23.5

ABSTRACT:

The invention provides isolated nucleic acids molecules and proteins, designated 27411, 23413, 22438, 23553, 25278, 26212, NARC SC1, NARC 10A, NARC 1, NARC 12, NARC 13, NARC 17, NARC 25, NARC 3, NARC 4, NARC 7, NARC 8, NARC 11, NARC 14A, NARC 15, NARC 16, NARC 19, NARC 20, NARC 26, NARC 27, NARC 28, NARC 30, NARC 5, NARC 6, NARC 9, NARC 10C, NARC 8B, NARC 9, NARC2A, NARC 16B, NARC 1C, NARC 1A, NARC 25, 86604 and 32222 nucleic acid molecules and proteins. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing said nucleic acid molecules, host cells into which the expression vectors have been introduced, nonhuman transgenic animals in which a said genes have been introduced or disrupted, fusion proteins, antigenic peptides and antibodies to said proteins. Diagnostic and therapeutic methods utilizing compositions of the invention are also provided.

☐ 15. Document ID: US 20030232375 A1

L4: Entry 15 of 65 File: PGPB Dec 18, 2003

PGPUB-DOCUMENT-NUMBER: 20030232375
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20030232375 A1

TITLE: Identification of a gene causing the most common form of Bardet-Biedl Syndrome and uses thereof

PUBLICATION-DATE: December 18, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Sheffield, Val C.	Iowa City	IA	US	
Mykytyn, Kirk	Iowa City	IA	US	
Nishimura, Darryl Y.	Coralville	IA	US	
Stone, Edwin M.	Iowa City	IA	US	
Searby, Charles C.	Iowa City	IA	US	

US-CL-CURRENT: 435/6; 435/320.1, 435/325, 435/456, 435/69.1, 530/350, 536/23.5

ABSTRACT:

The present invention relates to the identification of a gene, mutated at the most common locus now designated BBS1, that is involved in the genetic disease Bardet Biedl Syndrome (BBS), which is characterized by such diverse symptoms as obesity, diabetes, hypogonadism, mental retardation, renal cancer and other renal abnormalities, retinopathy and polydactyly or limb deformities. The human BBS1 protein disclosed herein is composed of 17 exons and spans approximately 23 kb. Methods of use for the gene, for example in diagnosis and therapy of BBS and in drug screening, also are described.

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | Claims | KWIC | Draw De

☐ 16. Document ID: US 20030186337 A1

L4: Entry 16 of 65 File: PGPB Oct 2, 2003

PGPUB-DOCUMENT-NUMBER: 20030186337
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20030186337 A1

TITLE: Novel death associated proteins, and THAP1 and PAR4 pathways in apoptosis control

PUBLICATION-DATE: October 2, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Girard, Jean-Philippe	Rebigue		FR	
Amalric, Francois	Toulouse		FR	
Roussigne, Myriam	La Bastide sur L'Hers		FR	
Kossida, Sophia	Basel		CH	
Clouaire, Thomas	Toulouse		FR	

US-CL-CURRENT: 435/7.23; 435/226, 435/320.1, 435/325, 435/69.1, 536/23.2

ABSTRACT:

The invention relates to genes and proteins of the THAP (THanatos (death)-Associated Protein) family comprising a THAP domain, and their use in diagnostics, treatment of disease, and in the identification of molecules for the treatment of disease. The invention also relates to the Par4 protein and SLC chemokine pathways, including the interaction of Par4 and SLC with THAP family proteins, and the recruitment and localization of Par4 to PML nuclear bodies.

☐ 17. Document ID: US 20030170645 A1

L4: Entry 17 of 65 File: PGPB Sep 11, 2003

PGPUB-DOCUMENT-NUMBER: 20030170645
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20030170645 A1

TITLE: Bardet-biedl susceptibility gene and uses thereof

PUBLICATION-DATE: September 11, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Sheffield, Val C.	Iowa City	IA	US	
Mykytyn, Kirk	Iowa City	IA	US	
Stone, Edwin M.	Iowa City	IA	US	

US-CL-CURRENT: 435/6; 435/183, 435/320.1, 435/325, 435/69.1, 536/23.2

ABSTRACT:

The present invention relates to the identification of a gene, now designated BBS4, that is involved in the genetic disease Bardet Biedl Syndrome (BBS), which is characterized by such diverse symptoms as obesity, diabetes, hypertension, mental retardation, renal cancer and other abnormalities, retinopathy and hypogonadism. The human BBS4 protein disclosed herein is 519 amino acids in length and is coded for by a gene spanning 16 exons. Homologs have been identified in mouse, rat, zebrafish. Methods of use for the gene, for example in diagnosis and therapy of BBS and in drug screening, also are described.

☐ 18. Document ID: US 20030166527 A1

L4: Entry 18 of 65 File: PGPB Sep 4, 2003

PGPUB-DOCUMENT-NUMBER: 20030166527
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20030166527 A1

TITLE: G-CSF analog compositions and methods

PUBLICATION-DATE: September 4, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Sarkar, Casim A.	Cambridge	MA	US	
Lauffenburger, Douglas A.	Cambridge	MA	US	
Tidor, Bruce	Lexington	MA	US	

US-CL-CURRENT: 514/12; 424/85.2, 435/320.1, 435/325, 435/69.4, 530/399, 536/23.5

ABSTRACT:

The present invention relates to granulocyte colony stimulating factor ("G-CSF") analog polypeptide compositions, related nucleic acids, expression constructs, host cells, and processes for recombinant production of the present G-CSF analogs. The concept detailed herein involves novel mutants of G-CSF, using single substitutions to amino acids, which were rationally chosen to affect the cellular trafficking of G-CSF and/or G-CSFR. In addition, pharmaceutical compositions, and methods of use are provided.

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | Claims | KWIC | Draw D

☐ 19. Document ID: US 20030166196 A1

L4: Entry 19 of 65 File: PGPB Sep 4, 2003

PGPUB-DOCUMENT-NUMBER: 20030166196
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20030166196 A1

TITLE: Fusion proteins and polynucleotides encoding gelonin sequences

PUBLICATION-DATE: September 4, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Better, Marc D.	Los Angeles	CA	US	

Carroll, Stephen F. Walnut Creek CA US

US-CL-CURRENT: 435/188.5; 435/69.1, 530/326, 530/350, 530/391.9, 536/23.2, 536/23.4, 536/23.6

ABSTRACT:

The present invention provides purified and isolated polynucleotides encoding Type I ribosome-inactivating proteins (RIPS) and analogs of the RIPs having a cysteine available for disulfide bonding to targeting molecules. Vectors comprising the polynucleotides and host cells transformed with the vectors are also provided. The RIPs and RIP analogs are particularly suited for use as components of cytotoxic therapeutic agents of the invention which include gene fusion products and immunoconjugates. Cytotoxic therapeutic agents or immunotoxins according to the present invention may be used to selectively eliminate any cell type to which the RIP component is targeted by the specific binding capacity of the second component of the agent, and are suited for treatment of diseases where the elimination of a particular cell type is a goal, such as autoimmune disease, cancer and graft-versus-host disease.

☐ 20. Document ID: US 20030166036 A1

L4: Entry 20 of 65 File: PGPB Sep 4, 2003

PGPUB-DOCUMENT-NUMBER: 20030166036
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20030166036 A1

TITLE: Protease and an aminopeptidase associated with development of benign prostatic hyperplasia (BPH)

PUBLICATION-DATE: September 4, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Mikolajczyk, Stephen D.	San Diego	CA	US	
Rittenhouse, Harry G.	Del Mar	CA	US	

US-CL-CURRENT: 435/23; 435/226

ABSTRACT:

Methods for identification and isolation of a benign prostate specific antigen (BPSA) protease and BPSA aminopeptidase are provided. The BPSA protease of the present invention preferentially cleaves prostate specific antigen (PSA) at residue Lys182 and does not react with the residue Arg85. The BPSA aminopeptidase cleaves BPSA between residues Ile1 and Val2 and between residues Lys146 and Leu147, but does not cleave BPSA at Ser183.

☐ 21. Document ID: US 20030152591 A1

L4: Entry 21 of 65 File: PGPB Aug 14, 2003

PGPUB-DOCUMENT-NUMBER: 20030152591
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20030152591 A1

TITLE: Hepatitis C virus genotype, and its use as prophylactic, therapeutic and diagnostic agent

PUBLICATION-DATE: August 14, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Sablon, Erwin	Merchtem		BE	
Van Doorn, Leen-Jan	Ridderkerk		NL	
Quint, Wim	Nootdrop		NL	

US-CL-CURRENT: 424/225.1; 424/228.1, 435/5, 435/6, 435/91.1

ABSTRACT:

The present invention relates to genomic nucleotide sequences and amino acid sequences corresponding to the non-coding and coding region of a new type of HCV. The invention relates to new HCV types and subtypes sequences which are different from the known HCV types and subtypes sequences. Particularly, the present invention relates to said new HCV type sequences; a process for preparing them, and their use for diagnosis, prophylaxis and therapy. More particularly, the present invention provides new type-specific sequences of the 5' NCR, Core, the E1 and the NS5 regions of the new HCV type. These new HCV sequences are useful to diagnose the presence of HCV type genotypes or serotypes in a biological sample. Moreover, the availability of these new type-specific sequences can increase the overall sensitivity of HCV detection and should also prove to be useful for prophylactic and therapeutic purposes.

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | Claims | KWMC | Draw De

☐ 22. Document ID: US 20030143702 A1

L4: Entry 22 of 65 File: PGPB Jul 31, 2003

PGPUB-DOCUMENT-NUMBER: 20030143702
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20030143702 A1

TITLE: Vesicular monoamine transporter gene therapy in parkinson's disease

PUBLICATION-DATE: July 31, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Kang, Un Jung	Northbrook	IL	US	

US-CL-CURRENT: 435/128; 435/325, 435/455, 435/456

ABSTRACT:

The present invention provides methods and compositions for the therapeutic intervention of Parkinson's disease. More particularly, methods of making and sequestering dopamine are disclosed. Additionally, methods of genetically modifying donor cells by gene transfer for grafting into the central nervous system to treat defective, diseased or damaged cells are disclosed. Methods and compositions for carrying out such gene transfer and grafting are described.

☐ 23. Document ID: US 20030139324 A1

L4: Entry 23 of 65 File: PGPB Jul 24, 2003

PGPUB-DOCUMENT-NUMBER: 20030139324
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20030139324 A1

TITLE: Tumor suppressor designated TS10q23.3

PUBLICATION-DATE: July 24, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Steck, Peter	Bellaire	TX	US	
Pershouse, Mark A.	Houston	TX	US	
Jasser, Samar A.	Houston	TX	US	
Yung, Alfred W.K.	Houston	TX	US	
Tavtigian, Sean V.	Salt Lake City	UT	US	

US-CL-CURRENT: 514/2; 435/184, 435/320.1, 435/325, 435/6, 435/7.23, 536/23.2

ABSTRACT:

A specific region of chromosome 10 (10q23.3) has been implicated by series of studies to contain a tumor suppressor gene involved in gliomas, as well as a number of other human cancers. One gene within this region was identified, and the corresponding coding region of the gene represents a novel 47 kD protein. A domain of this product has an exact match to the conserved catalytic domain of protein tyrosine phosphatases, indicating a possible functional role in phosphorylation events. Sequence analyses demonstrated the a number of exons of the gene were deleted in tumor cell lines used to define the 10q23.3 region, leading to the classification of this gene as a tumor suppressor. Further analyses have demonstrated the presence of a number of mutations in the gene in both glioma and prostate carcinoma cells. Methods for diagnosing and treating cancers related to

this tumor suppressor, designated as TS10q23.3, also are disclosed.

☐ 24. Document ID: US 20030138432 A1

L4: Entry 24 of 65 File: PGPB Jul 24, 2003

PGPUB-DOCUMENT-NUMBER: 20030138432
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20030138432 A1

TITLE: Selective cellular targeting: multifunctional delivery vehicles, multifunctional prodrugs, use as antineoplastic drugs

PUBLICATION-DATE: July 24, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Glazier, Arnold	Newton	MA	US	

US-CL-CURRENT: 424/178.1

ABSTRACT:

The present invention relates to the compositions, methods, and applications of a novel approach to selective cellular targeting. The purpose of this invention is to enable the selective delivery and/or selective activation of effector molecules to target cells for diagnostic or therapeutic purposes. The present invention relates to multi-functional prodrugs or targeting vehicles wherein each functionality is capable of enhancing targeting selectivity, affinity, intracellular transport, activation or detoxification. The present invention also relates to ultra-low dose, multiple target, multiple drug chemotherapy and targeted immunotherapy for cancer treatment.

☐ 25. Document ID: US 20030124593 A1

L4: Entry 25 of 65 File: PGPB Jul 3, 2003

PGPUB-DOCUMENT-NUMBER: 20030124593
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20030124593 A1

TITLE: Methods and compositions for the treatment and diagnosis of cellular proliferation disorders using 25943

PUBLICATION-DATE: July 3, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Williamson, Mark	Saugus	MA	US	
Rudolph-Owen, Laura A.	Jamaica Plain	MA	US	

US-CL-CURRENT: 435/6; 424/146.1, 435/7.21, 514/1, 514/2, 514/44

ABSTRACT:

The present invention relates to methods and compositions for the treatment and diagnosis of cellular proliferation disorders, including, but not limited to, breast cancer, ovarian cancer, lung cancer, and colon cancer. The invention further provides methods for identifying a compound capable of treating a cellular proliferation disorders disorder or modulating cellular proliferation. The invention also provides a method for modulating cellular proliferation, e.g., modulating cellular proliferation in a subject. In addition, the invention provides a method for treating a subject having a cellular proliferation disorder characterized by aberrant 25943 polypeptide activity or aberrant 25943 nucleic acid expression.

☐ 26. Document ID: US 20030114408 A1

L4: Entry 26 of 65 File: PGPB Jun 19, 2003

PGPUB-DOCUMENT-NUMBER: 20030114408
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20030114408 A1

TITLE: Methods and compositions for the diagnosis and treatment of cellular proliferation disorders using 86604

PUBLICATION-DATE: June 19, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Williamson, Mark	Saugus	MA	US	

US-CL-CURRENT: 514/44; 424/146.1, 435/6, 435/7.2, 514/1, 514/2

ABSTRACT:

The present invention provides methods and compositions for the diagnosis and treatment of cellular proliferation disorders, e.g., cancer, including, but not limited to colon, ovarian, and lung cancer. The invention further provides methods for identifying a compound capable of treating a cellular proliferation disorder. The invention also provides methods for identifying a compound capable of modulating a cellular proliferation disorder. In addition, the invention provides a method for treating a subject having a cellular proliferation disorder characterized by aberrant 86604 polypeptide activity or aberrant 86604 nucleic acid expression.

☐ 27. Document ID: US 20030113776 A1

L4: Entry 27 of 65 File: PGPB Jun 19, 2003

PGPUB-DOCUMENT-NUMBER: 20030113776
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20030113776 A1

TITLE: Methods and compositions for the treatment and diagnosis of cellular proliferation disorders using 54394

PUBLICATION-DATE: June 19, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Williamson, Mark	Saugus	MA	US	

US-CL-CURRENT: 435/6; 424/146.1, 435/7.21, 514/1, 514/2, 514/44

ABSTRACT:

The present invention relates to methods and compositions for the treatment and diagnosis of cellular proliferation disorders, including, but not limited to, breast cancer, ovarian cancer, lung cancer, and colon cancer. The invention further provides methods for identifying a compound capable of treating a cellular proliferation disorders disorder or modulating cellular proliferation. The invention also provides a method for modulating cellular proliferation, e.g., modulating cellular proliferation in a subject. In addition, the invention provides a method for treating a subject having a cellular proliferation disorder characterized by aberrant 54394 polypeptide activity or aberrant 54394 nucleic acid expression.

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | Claims | KWIC | Draw De

☐ 28. Document ID: US 20030108937 A1

L4: Entry 28 of 65 File: PGPB Jun 12, 2003

PGPUB-DOCUMENT-NUMBER: 20030108937
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20030108937 A1

TITLE: Methods and compositions for the diagnosis and treatment of cellular proliferation disorders using 20750

PUBLICATION-DATE: June 12, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Williamson, Mark	Saugus	MA	US	

US-CL-CURRENT: 435/6; 424/146.1, 435/7.21, 514/1, 514/2, 514/44

ABSTRACT:

The present invention provides methods and compositions for the diagnosis and treatment of cellular proliferation disorders, e.g., cancer, including, but not limited to colon, breast, and lung cancer. The invention further provides methods for identifying a compound capable of treating a cellular proliferation disorder. The invention also provides methods for identifying a compound capable of modulating a cellular proliferation disorder. In addition, the invention provides a method for treating a subject having a cellular proliferation disorder characterized by aberrant 20750 polypeptide activity or aberrant 20750 nucleic acid expression.

☐ 29. Document ID: US 20030087816 A1

L4: Entry 29 of 65 File: PGPB May 8, 2003

PGPUB-DOCUMENT-NUMBER: 20030087816
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20030087816 A1

TITLE: Novel proteins and nucleic acids encoding same

PUBLICATION-DATE: May 8, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Vermet, Corine	Gainesville	FL	US	
Fernandes, Elma	Branford	CT	US	
Shimkets, Richard	West Haven	CT	US	
Herrmann, John	Guilford	CT	US	
Majumder, Kumud	Stamford	CT	US	
MacDougall, John	Hamden	CT	US	
Mishra, Vishnu	Gainesville	FL	US	
Mezes, Peter S.	Old Lyme	CT	US	
Rastelli, Luca	Guilford	CT	US	

US-CL-CURRENT: 514/12; 435/320.1, 435/325, 435/69.1, 530/350, 536/23.5

ABSTRACT:

Disclosed herein are novel human nucleic acid sequences which encode polypeptides. Also disclosed are polypeptides encoded by these nucleic acid sequences, and antibodies which immunospecifically-bind to the polypeptide, as well as derivatives, variants, mutants, or fragments of the aforementioned polypeptide,

polynucleotide, or antibody. The invention further disclosed therapeutic, diagnostic and research methods for diagnosis, treatment, and prevention of disorders involving any one of these novel human nucleic acids and proteins.

☐ 30. Document ID: US 20030050470 A1

L4: Entry 30 of 65 File: PGPB Mar 13, 2003

PGPUB-DOCUMENT-NUMBER: 20030050470
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20030050470 A1

TITLE: Biomarkers and targets for diagnosis, prognosis and management of prostate disease, bladder and breast cancer

PUBLICATION-DATE: March 13, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
An, Gang	Oklahoma City	OK	US	
O'Hara, S. Mark	Oklahoma City	OK	US	
Ralph, David	Edmund	OK	US	
Veltri, Robert	Oklahoma City	OK	US	

US-CL-CURRENT: 536/24.3; 435/6

ABSTRACT:

Disclosed are diagnostic techniques for the detection of human prostate, bladder and breast cancer. Genetic probes and methods useful in monitoring the progression and diagnosis of prostate, bladder and breast cancer are described. The invention relates particularly to probes and methods for evaluating the presence of RNA species that are differentially expressed in prostate, bladder and breast cancer compared to normal human prostate, benign prostatic hyperplasia, or normal bladder or breast tissue.

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | Claims | KWIC | Draw De

☐ 31. Document ID: US 20030022285 A1

L4: Entry 31 of 65 File: PGPB Jan 30, 2003

PGPUB-DOCUMENT-NUMBER: 20030022285
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20030022285 A1

TITLE: Protein design automation for designing protein libraries with altered immunogenicity

PUBLICATION-DATE: January 30, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Chirino, Arthur J.	Camarillo	CA	US	
Dahiyat, Bassil I.	Altadena	CA	US	
Desjarlais, John	Pasadena	CA	US	

US-CL-CURRENT: 435/69.1; 703/11

ABSTRACT:

The present invention relates to the use of a variety of computational methods for modulating the immunogenicity of proteins by identifying and then altering potential amino acid sequences that elicit an immune response in a host organism. In particular, proteins will be screened for MHC binding sequences, T cell epitopes and B cell epitopes.

☐ 32. Document ID: US 20030017472 A1

L4: Entry 32 of 65 File: PGPB Jan 23, 2003

PGPUB-DOCUMENT-NUMBER: 20030017472
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20030017472 A1

TITLE: Novel, prostate-specific gene for diagnosis, prognosis and management of prostate cancer

PUBLICATION-DATE: January 23, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
An, Gang	Oklahoma City	OK	US	
Veltri, Robert	Oklahoma City	OK	US	

US-CL-CURRENT: 435/6; 435/183, 435/320.1, 435/325, 435/69.1, 435/7.23, 536/23.2

ABSTRACT:

Disclosed are nucleic acid and amino acid sequences encoded by a novel, prostate specific gene (UC41) and diagnostic techniques for the detection of human prostate cancer utilizing such nucleic acid and amino acid sequences. Genetic probes and methods useful in monitoring the progression and diagnosis of prostate cancer are described. Methods of treatment for prostate cancer utilizing antisense constructs or antibodies specific for UC41 gene products are also described.

☐ 33. Document ID: US 20030012792 A1

L4: Entry 33 of 65 File: PGPB Jan 16, 2003

PGPUB-DOCUMENT-NUMBER: 20030012792
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20030012792 A1

TITLE: Compositions and methods for inhibiting endothelial cell proliferation and regulating angiogenesis using cancer markers

PUBLICATION-DATE: January 16, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Holaday, John W.	Bethesda	MD	US	
Fortier, Anne H.	Germantown	MD	US	

US-CL-CURRENT: 424/185.1; 424/277.1

ABSTRACT:

Compositions and methods for regulating angiogenesis wherein the compositions comprise cancer markers are provided. Serine proteases and kallikreins exhibit potent antiangiogenic activity on human and other animal cells, particularly endothelial cells. More particularly, the use of a cancer marker, such as PSA, CEA, HCG, NSE, or CA19-9, to inhibit or ameliorate angiogenesis and angiogenesis-related diseases such as cancer, arthritis, macular degeneration, and diabetic retinopathy is disclosed.

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | Claims | KWIC | Draw De

☐ 34. Document ID: US 20020155115 A1

L4: Entry 34 of 65 File: PGPB Oct 24, 2002

PGPUB-DOCUMENT-NUMBER: 20020155115
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20020155115 A1

TITLE: Novel proteins and nucleic acids encoding same

PUBLICATION-DATE: October 24, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Vernet, Corine A.M.	North Branford	CT	US	
Fernandes, Elma R.	Branford	CT	US	
Shimkets, Richard A.	West Haven	CT	US	
Herrmann, John L.	Guilford	CT	US	

Majumder, Kumud	Stamford	CT	US
MacDougall, John R.	Hamden	CT	US
Mishra, Vishnu S.	Gainesville	FL	US
Mezes, Peter S.	Old Lyme	CT	US
Rastelli, Luca	Guilford	CT	US

US-CL-CURRENT: 424/155.1; 435/320.1, 435/325, 435/6, 435/7.23, 536/23.1

ABSTRACT:

Disclosed herein are novel human nucleic acid sequences which encode polypeptides. Also disclosed are polypeptides encoded by these nucleic acid sequences, and antibodies which immunospecifically-bind to the polypeptide, as well as derivatives, variants, mutants, or fragments of the aforementioned polypeptide, polynucleotide, or antibody. The invention further discloses therapeutic, diagnostic and research methods for diagnosis, treatment, and prevention of disorders involving any one of these novel human nucleic acids and proteins.

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | Claims | KWIC | Draw De

---

☐ 35. Document ID: US 20020151488 A1

L4: Entry 35 of 65 File: PGPB Oct 17, 2002

PGPUB-DOCUMENT-NUMBER: 20020151488
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20020151488 A1

TITLE: G-CSF analog compositions and methods

PUBLICATION-DATE: October 17, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Sarkar, Casim A.	Cambridge	MA	US	
Lauffenburger, Douglas A.	Cambridge	MA	US	

US-CL-CURRENT: 514/12; 424/85.2, 435/320.1, 435/325, 435/69.1, 530/399, 536/23.5

ABSTRACT:

The present invention relates to granulocyte colony stimulating factor ("G-CSF") polypeptide analog compositions. The concept detailed herein provides methods for screening G-CSF analogs, designed with one or more substitutions to amino acids, and selecting analogs for use as G-CSF replacements or antagonists, and may be generalizable beyond G-CSF analogs as well. In addition, pharmaceutical compositions and methods of use are provided for analogs so selected.

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | Claims | KWIC | Draw De

☐ 36. Document ID: US 20020150931 A1

L4: Entry 36 of 65 File: PGPB Oct 17, 2002

PGPUB-DOCUMENT-NUMBER: 20020150931
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20020150931 A1

TITLE: Bardet-biedl susceptibility gene and uses thereof

PUBLICATION-DATE: October 17, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Sheffield, Val	Iowa City	IA	US	
Nishimura, Darryl	Coralville	IA	US	
Stone, Edwin	Iowa City	IA	US	

US-CL-CURRENT: 435/6; 435/183, 435/320.1, 435/325, 435/69.1, 435/7.92, 536/23.2

ABSTRACT:

The present invention relates to the identification of a gene, now designated negevin (ngvn), that is involved in the genetic disease Bardet Biedl Syndrome (BBS), which is characterized by such diverse symptoms as obesity, diabetes, hypertension, mental retardation, renal cancer and other abnormalities, retinopathy and hypogonadism. The human NGVN protein disclosed herein is 731 amino acids in length and is coded for by a gene spanning 17 exons. Homologs have been identified in mouse, rat, zebrafish. Methods of use for the gene, for example in diagnosis and therapy of BBS and in drug screening, also are described.

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | Claims | KWIC | Draw De

☐ 37. Document ID: US 20020147323 A1

L4: Entry 37 of 65 File: PGPB Oct 10, 2002

PGPUB-DOCUMENT-NUMBER: 20020147323
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20020147323 A1

TITLE: 16224 and 69611, novel human kinases and uses thereof

PUBLICATION-DATE: October 10, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Bandaru, Rajasehkar	Watertown	MA	US	
Kapeller-Libermann, Rosana	Chestnut Hill	MA	US	

US-CL-CURRENT: 536/23.2; 435/194, 435/320.1, 435/325, 435/69.1

ABSTRACT:

The invention provides isolated nucleic acids molecules, designated HK nucleic acid molecules, which encode novel protein kinase family molecules. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing HK nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which an HK gene has been introduced or disrupted. The invention still further provides isolated HK polypeptides, fusion polypeptides, antigenic peptides and anti-HK antibodies. Diagnostic methods utilizing compositions of the invention are also provided.

☐ 38. Document ID: US 20020119466 A1

L4: Entry 38 of 65 File: PGPB Aug 29, 2002

PGPUB-DOCUMENT-NUMBER: 20020119466
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20020119466 A1

TITLE: 46863, a novel human methyltransferase and uses thereof

PUBLICATION-DATE: August 29, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Meyers, Rachel	Newton	MA	US	
Williamson, Mark	Saugus	MA	US	
Rudolph-Owen, Laura A.	Jamaica Plain	MA	US	

US-CL-CURRENT: 435/6; 435/193, 435/320.1, 435/325, 435/69.1, 435/7.23, 536/23.2

ABSTRACT:

The invention provides isolated nucleic acid molecules, designated TPRM nucleic acid molecules, which encode novel methyltransferase family members. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing TPRM nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a TPRM gene has been introduced or disrupted. The invention still further provides isolated TPRM proteins, fusion proteins, antigenic peptides and anti-TPRM antibodies. Diagnostic and therapeutic methods utilizing compositions of the invention are also provided.

☐ 39. Document ID: US 20020068281 A1

L4: Entry 39 of 65 File: PGPB Jun 6, 2002

PGPUB-DOCUMENT-NUMBER: 20020068281
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20020068281 A1

TITLE: Novel, prostate-specific gene for diagnosis, prognosis and management of prostate cancer

PUBLICATION-DATE: June 6, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
An, Gang	Oklahoma City	OK	US	
Veltri, Robert	Oklahoma City	OK	US	

US-CL-CURRENT: 435/6; 435/320.1, 435/325, 435/69.1, 536/23.2

ABSTRACT:

Disclosed are nucleic acid and amino acid sequences encoded by a novel, prostate specific gene (UC41) and diagnostic techniques for the detection of human prostate cancer utilizing such nucleic acid and amino acid sequences. Genetic probes and methods useful in monitoring the progression and diagnosis of prostate cancer are described. Methods of treatment for prostate cancer utilizing antisense constructs or antibodies specific for UC41 gene products are also described.

☐ 40. Document ID: US 20010036929 A1

L4: Entry 40 of 65 File: PGPB Nov 1, 2001

PGPUB-DOCUMENT-NUMBER: 20010036929
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20010036929 A1

TITLE: Xrcc3 is required for assembly of Rad51-complexes in vivo

PUBLICATION-DATE: November 1, 2001

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Weichselbaum, Ralph R.	Chicago	IL	US	
Bishop, Douglas K.	Chicago	IL	US	

US-CL-CURRENT: 514/44; 424/649, 514/34

ABSTRACT:

The present invention relates to the interaction of Rad51 and Xrcc3 to form a complex that mediates DNA repair in eukaryotic cells. A functional Rad51/Xrcc3 complex can be introduced into a cell to increase the resistance of the cell to DNA damaging agents. The invention also provides for a clinical application of a

regimen combining Rad51 and Xrcc3 to reduce the side effects of radiotherapy and chemotherapy in a patient. In addition, the invention discloses methods for identifying candidate substances that interact with the Rad51/Xrcc3 complex. In another embodiment of the invention, preventing the formation of the Rad51/Xrcc3 complex increases the susceptibility of a cell to DNA damaging agents. This strategy can be used in combination with a DNA damaging agent or factor to kill cancerous cells.

☐ 41. Document ID: US 20010011078 A1

L4: Entry 41 of 65 File: PGPB Aug 2, 2001

PGPUB-DOCUMENT-NUMBER: 20010011078
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20010011078 A1

TITLE: DNA fragmentation factor involved in apoptosis

PUBLICATION-DATE: August 2, 2001

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Wang, Xiaodong	Dallas	TX	US	
Liu, Xueson	Dallas	TX	US	

US-CL-CURRENT: 514/44; 424/93.2, 424/94.6, 435/196, 435/320.1, 435/6, 530/388.26, 536/23.2

ABSTRACT:

The invention provides methods and compositions relating to DNA Fragmentation Factor (DFF) polypeptides and related nucleic acids. More particularly, the present invention provides the sequence for the active subunit of DFF. The polypeptides may be produced recombinantly from host cells transformed from the disclosed DFF encoding nucleic acids or purified from human cells. The invention provides isolated DFF hybridization probes and primers capable of specifically hybridization with the disclosed DFF genes, DFF-specific binding agents such as specific antibodies, and methods of making and using the subject compositions.

☐ 42. Document ID: US 20010007748 A1

L4: Entry 42 of 65 File: PGPB Jul 12, 2001

PGPUB-DOCUMENT-NUMBER: 20010007748
PGPUB-FILING-TYPE: new-utility
DOCUMENT-IDENTIFIER: US 20010007748 A1

TITLE: Biomarkers and targets for diagnosis, prognosis and management of prostate disease

PUBLICATION-DATE: July 12, 2001

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
An, Gang	Oklahoma City	OK	US	
Vertri, Robert W.	Oklahoma City	OK	US	

US-CL-CURRENT: 435/6; 435/7.1, 536/23.1

ABSTRACT:

Disclosed are diagnostic techniques for the detection of human prostate disease. The invention relates particularly to probes and methods for evaluating the presence of RNA species that are differentially expressed in metastatic prostate cancer compared to normal human prostate, benign prostatic hyperplasia, and non-metastatic prostate cancer. The invention also relates to probes and methods for evaluating the presence of RNA species that are differentially expressed in the peripheral blood of individuals with the disease state compared to normal healthy individuals. Described are methods of therapeutic use for genes identified as differentially expressed in metastatic prostate cancer, and means for screening pharmaceuticals effective in treatment of prostate cancer.

☐ 43. Document ID: US 6790648 B2

L4: Entry 43 of 65 File: USPT Sep 14, 2004

US-PAT-NO: 6790648
DOCUMENT-IDENTIFIER: US 6790648 B2

TITLE: DNA fragmentation factor involved in apoptosis

DATE-ISSUED: September 14, 2004

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Wang; Xiaodong	Dallas	TX		
Liu; Xuesong	Dallas	TX		

US-CL-CURRENT: 435/196; 435/252.3, 435/320.1, 435/69.1, 530/300, 530/321, 530/326, 536/23.2

ABSTRACT:

The invention provides methods and compositions relating to DNA Fragmentation Factor (DFF) polypeptides and related nucleic acids. More particularly, the present invention provides the sequence for the active subunit of DFF. The polypeptides may be produced recombinantly from host cells transformed from the disclosed DFF

encoding nucleic acids or purified from human cells. The invention provides isolated DFF, hybridization probes and primers capable of specifically hybridization with the disclosed DFF genes, DFF-specific binding agents such as specific antibodies, and methods of making and using the subject compositions.

5 Claims, 1 Drawing figures
Exemplary Claim Number: 1
Number of Drawing Sheets: 1

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | Claims | KWIC | Draw De

---

☐ 44. Document ID: US 6790628 B2

L4: Entry 44 of 65 File: USPT Sep 14, 2004

US-PAT-NO: 6790628
DOCUMENT-IDENTIFIER: US 6790628 B2

TITLE: Method for screening analogs of G-CSF

DATE-ISSUED: September 14, 2004

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Sarkar; Casim A.	Cambridge	MA		
Lauffenburger; Douglas A.	Cambridge	MA		

US-CL-CURRENT: 435/7.21; 435/7.1, 435/7.2

ABSTRACT:

The present invention relates to granulocyte colony stimulating factor ("G-CSF") polypeptide analog compositions. The concept detailed herein provides methods for screening G-CSF analogs, designed with one or more substitutions to amino acids, and selecting analogs for use as G-CSF replacements or antagonists, and may be generalizable beyond G-CSF analogs as well. In addition, pharmaceutical compositions and methods of use are provided for analogs so selected.

5 Claims, 1 Drawing figures
Exemplary Claim Number: 1
Number of Drawing Sheets: 1

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | Claims | KWIC | Draw De

---

☐ 45. Document ID: US 6743906 B1

L4: Entry 45 of 65 File: USPT Jun 1, 2004

US-PAT-NO: 6743906
DOCUMENT-IDENTIFIER: US 6743906 B1

TITLE: PPP2R1B is a tumor suppressor

DATE-ISSUED: June 1, 2004

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Evans; Glen A.	San Marcos	CA		
Wang; Steven Siqing	The Woodlands	TX		
Esplin; Edward D.	Dallas	TX		
Li; Jia Ling	Dallas	TX		
Huang; Liying	Guang Dong			CN

US-CL-CURRENT: 536/23.5; 536/24.1, 536/24.2

ABSTRACT:

The present invention identifies the PPP2R1B gene, as a human tumor suppressor gene. Sequencing of the PPP2R1B revealed that the gene is located on human chromosome 11q22-24 and that gene were mutated in tumors and tumor cell lines, leading to the classification of this gene as a tumor suppressor. Further analyses have demonstrated the presence of a number of mutations in the gene in lung, colon, breast and cervical cancer cells. Methods for diagnosing and treating cancers related to this tumor suppressor also are disclosed.

8 Claims, 15 Drawing figures
Exemplary Claim Number: 1
Number of Drawing Sheets: 11

☐ 46. Document ID: US 6737052 B1

L4: Entry 46 of 65 File: USPT May 18, 2004

US-PAT-NO: 6737052
DOCUMENT-IDENTIFIER: US 6737052 B1

TITLE: Induction of programmed cell death by N5 gene

DATE-ISSUED: May 18, 2004

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Goodrich; David W.	Sugar Land	TX		
Doostzadeh; Jaleh	Fremont	CA		
Yin; Shenmin	Houston	TX		

US-CL-CURRENT: 424/93.2; 424/93.21, 424/93.6, 435/320.1, 435/455, 435/456

ABSTRACT:

The present invention concerns methods and compositions for treating cancer in a subject. These methods and compositions utilize the activities associated with the N5 gene product, p84N5. p84N5 contains a functional death domain, can interact with the retinoblastoma gene product and is normally localized to the nucleus of cells. Increasing the activity level of p84N5 in cancer cells is beneficial for the treatment of cancer.

17 Claims, 54 Drawing figures
Exemplary Claim Number: 16
Number of Drawing Sheets: 29

☐ 47. Document ID: US 6649742 B1

L4: Entry 47 of 65 File: USPT Nov 18, 2003

US-PAT-NO: 6649742
DOCUMENT-IDENTIFIER: US 6649742 B1

TITLE: Immunotoxins comprising ribosome-inactivating proteins

DATE-ISSUED: November 18, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Better; Marc D.	Los Angeles	CA		
Carroll; Stephen F.	Walnut Creek	CA		
Studnicka; Gary M.	Santa Monica	CA		

US-CL-CURRENT: 530/387.3; 530/866

ABSTRACT:

The present invention provides purified and isolated polynucleotides encoding Type I ribosome-inactivating proteins (RIPs) and analogs of the RIPs having a cysteine available for disulfide bonding to targeting molecules. Vectors comprising the polynucleotides and host cells transformed with the vectors are also provided. The RIPs and RIP analogs are particularly suited for use as components of cytotoxic therapeutic agents of the invention which include gene fusion products and immunoconjugates. Cytotoxic therapeutic agents or immunotoxins according to the present invention may be used to selectively eliminate any cell type to which the RIP component is targeted by the specific binding capacity of the second component of the agent, and are suited for treatment of diseases where the elimination of a particular cell type is a goal, such as autoimmune disease, cancer and graft-versus-host disease.

20 Claims, 15 Drawing figures
Exemplary Claim Number: 1
Number of Drawing Sheets: 15

☐ 48. Document ID: US 6506607 B1

L4: Entry 48 of 65 File: USPT Jan 14, 2003

US-PAT-NO: 6506607
DOCUMENT-IDENTIFIER: US 6506607 B1

TITLE: Methods and compositions for the identification and assessment of prostate cancer therapies and the diagnosis of prostate cancer

DATE-ISSUED: January 14, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Shyjan; Andrew W.	Nahant	MA		

US-CL-CURRENT: 436/94; 435/6, 435/91.1, 436/64, 536/23.1

ABSTRACT:

The invention concerns two classes of differentially regulated genes: 1) genes that are more highly expressed in prostate cancer cells treated with testosterone than in untreated prostate cancer cells; and 2) genes that are more highly expressed in prostate cancer cells treated with bicalutamide, an anti-androgenic compound, than in untreated prostate cancer cells. Disclosed are methods for selecting and monitoring the effectiveness of therapeutic agents used for the treatment of prostate cancer. Also disclosed are methods for identifying novel therapeutic agents for the treatment of prostate cancer and methods and compositions for preventing, treating, and diagnosing prostate cancer.

4 Claims, 1 Drawing figures
Exemplary Claim Number: 1
Number of Drawing Sheets: 1

☐ 49. Document ID: US 6506378 B1

L4: Entry 49 of 65 File: USPT Jan 14, 2003

US-PAT-NO: 6506378
DOCUMENT-IDENTIFIER: US 6506378 B1

TITLE: Vesicular monoamine transporter gene therapy in Parkinson's disease

DATE-ISSUED: January 14, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Kang; Un Jung	Northbrook	IL		

US-CL-CURRENT: 424/93.21; 424/93.1, 424/93.2, 435/320.1, 435/325, 435/375, 435/69.1, 514/44, 536/23.1, 536/23.5

ABSTRACT:

The present invention provides methods and compositions for the therapeutic intervention of Parkinson's disease. More particularly, methods of making and sequestering dopamine are disclosed. Additionally, methods of genetically modifying donor cells by gene transfer for grafting into the central nervous system to treat defective, diseased or damaged cells are disclosed. Methods and compositions for carrying out such gene transfer and grafting are described.

22 Claims, 24 Drawing figures
Exemplary Claim Number: 1
Number of Drawing Sheets: 5

☐ 50. Document ID: US 6482795 B1

L4: Entry 50 of 65 File: USPT Nov 19, 2002

US-PAT-NO: 6482795
DOCUMENT-IDENTIFIER: US 6482795 B1

TITLE: Tumor suppressor designated TS10q23.3

DATE-ISSUED: November 19, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Steck; Peter	Bellaire	TX		
Pershouse; Mark A.	Houston	TX		
Jasser; Samar A.	Houston	TX		
Yung; Alfred W. K.	Houston	TX		
Tavtigian; Sean V.	Salt Lake City	UT		

US-CL-CURRENT: 514/2; 514/12, 514/21, 530/350

ABSTRACT:

A specific region of chromosome 10 (10q23.3) has been implicated by series of studies to contain a tumor suppressor gene involved in gliomas, as well as a number of other human cancers. One gene within this region was identified, and the corresponding coding region of the gene represents a novel 47 kD protein. A domain of this product has an exact match to the conserved catalytic domain of protein tyrosine phosphatases, indicating a possible functional role in phosphorylation events. Sequence analyses demonstrated the a number of exons of the gene were deleted in tumor cell lines used to define the 10q23.3 region, leading to the classification of this gene as a tumor suppressor. Further analyses have demonstrated the presence of a number of mutations in the gene in both glioma and prostate carcinoma cells. Methods for diagnosing and treating cancers related to this tumor suppressor, designated as TS10q23.3, also are disclosed.

4 Claims, 51 Drawing figures
Exemplary Claim Number: 1
Number of Drawing Sheets: 43

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | Claims | KWIC | Draw. De

☐ 51. Document ID: US 6376217 B1

L4: Entry 51 of 65 File: USPT Apr 23, 2002

US-PAT-NO: 6376217
DOCUMENT-IDENTIFIER: US 6376217 B1

TITLE: Fusion proteins and polynucleotides encoding gelonin sequences

DATE-ISSUED: April 23, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Better; Marc D.	Los Angeles	CA		
Carroll; Stephen F.	Walnut Creek	CA		

US-CL-CURRENT: 435/69.1; 530/326, 530/350, 530/391.9, 536/23.2, 536/23.4, 536/23.6

ABSTRACT:

The present invention provides purified and isolated polynucleotides encoding Type I ribosome-inactivating proteins (RIPS) and analogs of the RIPs having a cysteine available for disulfide bonding to targeting molecules. Vectors comprising the polynucleotides and host cells transformed with the vectors are also provided. The RIPs and RIP analogs are particularly suited for use as components of cytotoxic therapeutic agents of the invention which include gene fusion products and immunoconjugates. Cytotoxic therapeutic agents or immunotoxins according to the present invention may be used to selectively eliminate any cell type to which the RIP component is targeted by the specific binding capacity of the second component of the agent, and are suited for treatment of diseases where the elimination of a particular cell type is a goal, such as autoimmune disease, cancer and graft-versus-host disease.

15 Claims, 15 Drawing figures
Exemplary Claim Number: 1
Number of Drawing Sheets: 15

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | Claims | KWIC | Draw. De

☐ 52. Document ID: US 6369195 B1

L4: Entry 52 of 65 File: USPT Apr 9, 2002

US-PAT-NO: 6369195
DOCUMENT-IDENTIFIER: US 6369195 B1

**** See image for Certificate of Correction ****

TITLE: Prostate-specific gene for diagnosis, prognosis and management of prostate cancer

DATE-ISSUED: April 9, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
An; Gang	Oklahoma City	OK		
Veltri; Robert	Oklahoma City	OK		

US-CL-CURRENT: 530/324; 435/6, 435/91.1, 435/91.2, 530/325, 530/326, 530/327, 530/328, 530/333, 530/850, 530/866

ABSTRACT:

Disclosed are nucleic acid and amino acid sequences encoded by a novel, prostate specific gene (UC41) and diagnostic techniques for the detection of human prostate cancer utilizing such nucleic acid and amino acid sequences. Genetic probes and methods useful in monitoring the progression and diagnosis of prostate cancer are described. Methods of treatment for prostate cancer utilizing antisense constructs or antibodies specific for UC41 gene products are also described.

21 Claims, 13 Drawing figures
Exemplary Claim Number: 1
Number of Drawing Sheets: 10

☐ 53. Document ID: US 6218529 B1

L4: Entry 53 of 65 File: USPT Apr 17, 2001

US-PAT-NO: 6218529
DOCUMENT-IDENTIFIER: US 6218529 B1
**** See image for Certificate of Correction ****

TITLE: Biomarkers and targets for diagnosis, prognosis and management of prostate, breast and bladder cancer

DATE-ISSUED: April 17, 2001

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
An; Gang	Oklahoma City	OK		
O'Hara; S. Mark	Oklahoma City	OK		
Ralph; David	Edmund	OK		
Veltri; Robert	Oklahoma City	OK		

US-CL-CURRENT: 536/24.33; 435/6, 536/23.1, 536/23.4, 536/23.5, 536/24.31

ABSTRACT:

Disclosed are diagnostic techniques for the detection of human prostate, bladder and breast cancer. Genetic probes and methods useful in monitoring the progression and diagnosis of prostate, bladder and breast cancer are described. The invention relates particularly to probes and methods for evaluating the presence of RNA species that are differentially expressed in prostate, bladder and breast cancer compared to normal human prostate, benign prostatic hyperplasia, or normal bladder or breast tissue.

38 Claims, 22 Drawing figures
Exemplary Claim Number: 1
Number of Drawing Sheets: 12

☐ 54. Document ID: US 6171796 B1

L4: Entry 54 of 65 File: USPT Jan 9, 2001

US-PAT-NO: 6171796
DOCUMENT-IDENTIFIER: US 6171796 B1

TITLE: Biomarkers and targets for diagnosis prognosis and management of prostate disease

DATE-ISSUED: January 9, 2001

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
An; Gang	Oklahoma City	OK		
Vertri; Robert W.	Oklahoma City	OK		

US-CL-CURRENT: 435/6; 435/7.1, 435/91.2, 530/350, 530/387.1, 530/388.1

ABSTRACT:

Disclosed are diagnostic techniques for the detection of human prostate disease. The invention relates particularly to probes and methods for evaluating the presence of RNA species that are differentially expressed in metastatic prostate cancer compared to normal human prostate, benign prostatic hyperplasia, and non-metastatic prostate cancer. The invention also relates to probes and methods for evaluating the presence of RNA species that are differentially expressed in the peripheral blood of individuals with the disease state compared to normal healthy individuals. Described are methods of therapeutic use for genes identified as differentially expressed in metastatic prostate cancer, and means for screening pharmaceuticals effective in treatment of prostate cancer.

16 Claims, 0 Drawing figures
Exemplary Claim Number: 1

☐ 55. Document ID: US 6165737 A

L4: Entry 55 of 65 File: USPT Dec 26, 2000

US-PAT-NO: 6165737
DOCUMENT-IDENTIFIER: US 6165737 A

TITLE: DNA fragmentation factor involved in apoptosis

DATE-ISSUED: December 26, 2000

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Wang; Xiaodong	Dallas	TX		
Liu; Xuesong	Dallas	TX		

US-CL-CURRENT: 435/7.6; 435/23, 435/252.3, 435/252.33, 435/320.1, 435/7.91, 536/23.2

ABSTRACT:

The invention provides methods and compositions relating to DNA Fragmentation Factor (DFF) polypeptides and related nucleic acids. More particularly, the present invention provides the sequence for the active subunit of DFF. The polylpeptides may be produced recombinantly from host cells transformed from the disclosed DFF encoding nucleic acids or purified from human cells. The invention provides isolated DFF hybridization probes and primers capable of specifically hybridization with the disclosed DFF genes, DFF-specific binding agents such as specific antibodies, and methods of making and using the subject compositions.

20 Claims, 1 Drawing figures
Exemplary Claim Number: 1
Number of Drawing Sheets: 1

Full | Title | Citation | Front | Review | Classification | Date | Reference | Claims | KWMC | Draw De

☐ 56. Document ID: US 6156515 A

L4: Entry 56 of 65 File: USPT Dec 5, 2000

US-PAT-NO: 6156515
DOCUMENT-IDENTIFIER: US 6156515 A
** See image for Certificate of Correction **

TITLE: Prostate-specific gene for diagnosis, prognosis and management of prostate cancer

DATE-ISSUED: December 5, 2000

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY

An; Gang	Oklahoma City	OK
Veltri; Robert	Oklahoma City	OK

US-CL-CURRENT: 435/6; 435/91.2, 435/91.5, 435/91.51, 536/24.31, 536/24.33

ABSTRACT:

Disclosed are nucleic acid and amino acid sequences encoded by a novel, prostate specific gene (UC41) and diagnostic techniques for the detection of human prostate cancer utilizing such nucleic acid and amino acid sequences. Genetic probes and methods useful in monitoring the progression and diagnosis of prostate cancer are described. Methods of treatment for prostate cancer utilizing antisense constructs or antibodies specific for UC41 gene products are also described.

14 Claims, 13 Drawing figures
Exemplary Claim Number: 1
Number of Drawing Sheets: 10

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | Claims | KWIC | Draw De

---

☐ 57. Document ID: US 6147192 A

L4: Entry 57 of 65 File: USPT Nov 14, 2000

US-PAT-NO: 6147192
DOCUMENT-IDENTIFIER: US 6147192 A

TITLE: Tub interactor (TI) polypeptides and uses therefor

DATE-ISSUED: November 14, 2000

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Gimeno; Carlos J.	Wellesley	MA		
Errada; Patrick R.	Cambridge	MA		

US-CL-CURRENT: 530/350

ABSTRACT:

The present invention provides a novel tub interactor (TI) polypeptides, as well as TI fusion polypeptides, and antigenic peptides.

41 Claims, 6 Drawing figures
Exemplary Claim Number: 1
Number of Drawing Sheets: 15

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | Claims | KWIC | Draw De

---

☐ 58. Document ID: US 6146850 A

L4: Entry 58 of 65 File: USPT Nov 14, 2000

US-PAT-NO: 6146850
DOCUMENT-IDENTIFIER: US 6146850 A

TITLE: Proteins encoding gelonin sequences

DATE-ISSUED: November 14, 2000

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Better; Marc D.	Los Angeles	CA		
Carroll; Stephen F.	Walnut Creek	CA		

US-CL-CURRENT: 435/69.1; 530/326, 530/350, 530/391.9, 536/23.2, 536/23.4, 536/23.6

ABSTRACT:

The present invention provides purified proteins that contain gelonin amino acid sequences that have enzymatic activity.

4 Claims, 15 Drawing figures
Exemplary Claim Number: 1
Number of Drawing Sheets: 15

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | Claims | KWIC | Draw De

---

☐ 59. Document ID: US 6146631 A

L4: Entry 59 of 65 File: USPT Nov 14, 2000

US-PAT-NO: 6146631
DOCUMENT-IDENTIFIER: US 6146631 A

TITLE: Immunotoxins comprising ribosome-inactivating proteins

DATE-ISSUED: November 14, 2000

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Better; Marc D.	Los Angeles	CA		
Carroll; Stephen F.	Walnut Creek	CA		
Studnicka; Gary M.	Santa Monica	CA		

US-CL-CURRENT: 424/183.1; 424/134.1, 424/172.1, 514/12, 514/13, 530/326, 530/370, 530/387.3, 530/391.7, 530/391.9

ABSTRACT:

The present invention provides purified and isolated polynucleotides encoding Type I ribosome-inactivating proteins (RIPS) and analogs of the RIPs having a cysteine available for disulfide bonding to targeting molecules. Vectors comprising the polynucleotides and host cells transformed with the vectors are also provided. The RIPs and RIP analogs are particularly suited for use as components of cytotoxic therapeutic agents of the invention which include gene fusion products and immunoconjugates. Cytotoxic therapeutic agents or immunotoxins according to the present invention may be used to selectively eliminate any cell type to which the RIP component is targeted by the specific binding capacity of the second component of the agent, and are suited for treatment of diseases where the elimination of a particular cell type is a goal, such as autoimmune disease, cancer and graft-versus-host disease.

54 Claims, 14 Drawing figures
Exemplary Claim Number: 1
Number of Drawing Sheets: 15

☐ 60. Document ID: US 5972615 A

L4: Entry 60 of 65 File: USPT Oct 26, 1999

US-PAT-NO: 5972615
DOCUMENT-IDENTIFIER: US 5972615 A

TITLE: Biomarkers and targets for diagnosis, prognosis and management of prostate disease

DATE-ISSUED: October 26, 1999

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
An; Gang	Oklahoma City	OK		
Vertri; Robert W.	Oklahoma City	OK		

US-CL-CURRENT: 435/6; 435/810, 435/91.2, 435/91.5, 536/23.1, 536/24.3, 536/24.31, 536/24.32, 536/24.33

ABSTRACT:

Disclosed are diagnostic techniques for the detection of human prostate disease. The invention relates particularly to probes and methods for evaluating the presence of RNA species that are differentially expressed in metastatic prostate cancer compared to normal human prostate, benign prostatic hyperplasia, and non-metastatic prostate cancer. The invention also relates to probes and methods for evaluating the presence of RNA species that are differentially expressed in the peripheral blood of individuals with the disease state compared to normal healthy individuals. Described are methods of therapeutic use for genes identified as differentially expressed in metastatic prostate cancer, and means for screening pharmaceuticals effective in treatment of prostate cancer.

23 Claims, 0 Drawing figures
Exemplary Claim Number: 1

☐ 61. Document ID: US 5955306 A

L4: Entry 61 of 65 File: USPT Sep 21, 1999

US-PAT-NO: 5955306
DOCUMENT-IDENTIFIER: US 5955306 A
**** See image for Certificate of Correction ****

TITLE: Genes encoding proteins that interact with the tub protein

DATE-ISSUED: September 21, 1999

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Gimeno; Carlos J.	Wellesley	MA		
Errada; Patrick R.	Cambridge	MA		

US-CL-CURRENT: 435/69.1; 435/252.3, 435/254.11, 435/320.1, 435/325, 435/71.1, 536/23.5, 536/24.3, 536/24.31

ABSTRACT:

The present invention relates to the discovery of novel genes encoding Tub interactor (TI) polypeptides. Therapeutics, diagnostics and screening assays based on these molecules are also disclosed.

23 Claims, 6 Drawing figures
Exemplary Claim Number: 1
Number of Drawing Sheets: 15

Full | Title | Citation | Front | Review | Classification | Date | Reference | References | Attachments | Claims | KWIC | Draw. De

☐ 62. Document ID: US 5837491 A

L4: Entry 62 of 65 File: USPT Nov 17, 1998

US-PAT-NO: 5837491
DOCUMENT-IDENTIFIER: US 5837491 A

TITLE: Polynucleotides encoding gelonin sequences

DATE-ISSUED: November 17, 1998

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Better; Marc D.	Los Angeles	CA		

Carroll; Stephen F.	Walnut Creek	CA
Studnicka; Gary M.	Santa Monica	CA

US-CL-CURRENT: 435/69.1; 435/252.3, 435/320.1, 536/23.4, 536/23.53, 536/23.6

ABSTRACT:

The present invention provides purified and isolated polynucleotides encoding Type I ribosome-inactivating proteins (RIPs) and analogs of the RIPs having a cysteine available for disulfide bonding to targeting molecules. Vectors comprising the polynucleotides and host cells transformed with the vectors are also provided. The RIPs and RIP analogs are particularly suited for use as components of cytotoxic therapeutic agents of the invention which include gene fusion products and immunoconjugates. Cytotoxic therapeutic agents or immunotoxins according to the present invention may be used to selectively eliminate any cell type to which the RIP component is targeted by the specific binding capacity of the second component of the agent and are suited for treatment of diseases where the elimination of a particular cell type is a goal, such as autoimmune disease, cancer and graft-versus-host disease.

20 Claims, 15 Drawing figures
Exemplary Claim Number: 1,2
Number of Drawing Sheets: 15

☐ 63. Document ID: US 5756699 A

L4: Entry 63 of 65 File: USPT May 26, 1998

US-PAT-NO: 5756699
DOCUMENT-IDENTIFIER: US 5756699 A
**** See image for Certificate of Correction ****

TITLE: Immunotoxins comprising ribosome-inactivating proteins

DATE-ISSUED: May 26, 1998

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Better; Marc D.	Los Angeles	CA		
Carroll; Stephen F.	Walnut Creek	CA		
Studnicka; Gary M.	Santa Monica	CA		

US-CL-CURRENT: 536/23.4; 435/69.4, 435/69.5, 435/69.7, 536/23.51, 536/23.52, 536/23.53, 536/23.6

ABSTRACT:

The present invention provides purified and isolated polynucleotides encoding Type I ribosome-inactivating proteins (RIPs) and analogs of the RIPs having a cysteine available for disulfide bonding to targeting molecules. Vectors comprising the polynucleotides and host cells transformed with the vectors are also provided. The

RIPs and RIP analogs are particularly suited for use as components of cytotoxic therapeutic agents of the invention which include gene fusion products and immunoconjugates. Cytotoxic therapeutic agents or immunotoxins according to the present invention may be used to selectively eliminate any cell type to which the RIP component is targeted by the specific binding capacity of the second component of the agent, and are suited for treatment of diseases where the elimination of a particular cell type is a goal, such as autoimmune disease, cancer and graft-versus-host disease.

53 Claims, 15 Drawing figures
Exemplary Claim Number: 1
Number of Drawing Sheets: 15

☐ 64. Document ID: US 5744580 A

L4: Entry 64 of 65 File: USPT Apr 28, 1998

US-PAT-NO: 5744580
DOCUMENT-IDENTIFIER: US 5744580 A

TITLE: Immunotoxins comprising ribosome-inactivating proteins

DATE-ISSUED: April 28, 1998

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Better; Marc D.	Los Angeles	CA		
Carroll; Stephen F.	Walnut Creek	CA		
Studnicka; Gary M.	Santa Monica	CA		

US-CL-CURRENT: 530/377; 530/351, 530/370, 530/387.3, 530/391.1, 530/391.5, 530/391.7, 530/391.9, 530/399

ABSTRACT:

The present invention provides purified and isolated polynucleotides encoding Type I ribosome-inactivating proteins (RIPS) and analogs of the RIPs having a cysteine available for disulfide bonding to targeting molecules. Vectors comprising the polynucleotides and host cells transformed with the vectors are also provided. The RIPs and RIP analogs are particularly suited for use as components of cytotoxic therapeutic agents of the invention which include gene fusion products and immunoconjugates. Cytotoxic therapeutic agents or immunotoxins according to the present invention may be used to selectively eliminate any cell type to which the RIP component is targeted by the specific binding capacity of the second component of the agent, and are suited for treatment of diseases where the elimination of a particular cell type is a goal, such as autoimmune disease, cancer and graft-versus-host disease.

36 Claims, 15 Drawing figures
Exemplary Claim Number: 1
Number of Drawing Sheets: 15

☐ 65. Document ID: US 5621083 A

L4: Entry 65 of 65 File: USPT Apr 15, 1997

US-PAT-NO: 5621083
DOCUMENT-IDENTIFIER: US 5621083 A

TITLE: Immunotoxins comprising ribosome-inactivating proteins

DATE-ISSUED: April 15, 1997

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Better; Marc D.	Los Angeles	CA		
Carroll; Stephen F.	Walnut Creek	CA		
Studnicka; Gary M.	Santa Monica	CA		

US-CL-CURRENT: 530/391.9; 530/326, 530/370, 530/387.3, 530/391.7, 536/23.53

ABSTRACT:

The present invention provides purified and isolated polynucleotides encoding Type I ribosome-inactivating proteins (RIPs) and analogs of the RIPs having a cysteine available for disulfide bonding to targeting molecules. Vectors comprising the polynucleotides and host cells transformed with the vectors are also provided. The RIPs and RIP analogs are particularly suited for use as components of cytotoxic therapeutic agents of the invention which include gene fusion products and immunoconjugates. Cytotoxic therapeutic agents or immunotoxins according to the present invention may be used to selectively eliminate any cell type to which the RIP component is targeted by the specific binding capacity of the second component of the agent, and are suited for treatment of diseases where the elimination of a particular cell type is a goal, such as autoimmune disease, cancer and graft-versus-host disease.

10 Claims, 15 Drawing figures
Exemplary Claim Number: 1
Number of Drawing Sheets: 15

Full | Title | Citation | Front | Review | Classification | Date | Reference | Claims | KWIC | Draw De

Clear | Generate Collection | Print | Fwd Refs | Bkwd Refs | Generate OACS

Term	Documents
SITE	532169
SITES	288747
MOTIF	27172

MOTIFS	19779
SEQUENCE	0
SEQUENCE	872205
SEQUENCES	248404
CLEAV$3	0
CLEAV	570
CLEAVA	809
CLEAVAA	1
(L3 AND CLEAV$3 (SITE|MOTIF|SEQUENCE)).PGPB,USPT,USOC.	65

There are more results than shown above. Click here to view the entire set.

Display Format: - Change Format

Previous Page Next Page Go to Doc#

FILE 'HOME' ENTERED AT 12:49:11 ON 28 APR 2005

=> file medicine bioscience dissabs
FILE 'DRUGMONOG' ACCESS NOT AUTHORIZED

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.21	0.21

FILE 'ADISCTI' ENTERED AT 12:49:30 ON 28 APR 2005
COPYRIGHT (C) 2005 Adis Data Information BV

FILE 'ADISINSIGHT' ENTERED AT 12:49:30 ON 28 APR 2005
COPYRIGHT (C) 2005 Adis Data Information BV

FILE 'ADISNEWS' ENTERED AT 12:49:30 ON 28 APR 2005
COPYRIGHT (C) 2005 Adis Data Information BV

FILE 'BIOSIS' ENTERED AT 12:49:30 ON 28 APR 2005
Copyright (c) 2005 The Thomson Corporation

FILE 'BIOTECHNO' ENTERED AT 12:49:30 ON 28 APR 2005
COPYRIGHT (C) 2005 Elsevier Science B.V., Amsterdam. All rights reserved.

FILE 'CANCERLIT' ENTERED AT 12:49:30 ON 28 APR 2005

FILE 'CAPLUS' ENTERED AT 12:49:30 ON 28 APR 2005
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2005 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'CEN' ENTERED AT 12:49:30 ON 28 APR 2005
COPYRIGHT (C) 2001 American Chemical Society (ACS)

FILE 'DDFB' ENTERED AT 12:49:30 ON 28 APR 2005
COPYRIGHT (C) 2005 THE THOMSON CORPORATION

FILE 'DDFU' ACCESS NOT AUTHORIZED

FILE 'DGENE' ENTERED AT 12:49:30 ON 28 APR 2005
COPYRIGHT (C) 2005 THE THOMSON CORPORATION

FILE 'DISSABS' ENTERED AT 12:49:30 ON 28 APR 2005
COPYRIGHT (C) 2005 ProQuest Information and Learning Company; All Rights Reserved.

FILE 'DRUGB' ENTERED AT 12:49:30 ON 28 APR 2005
COPYRIGHT (C) 2005 THE THOMSON CORPORATION

FILE 'DRUGMONOG2' ENTERED AT 12:49:30 ON 28 APR 2005
COPYRIGHT (C) 2005 IMSWORLD Publications Ltd

FILE 'DRUGU' ENTERED AT 12:49:30 ON 28 APR 2005
COPYRIGHT (C) 2005 THE THOMSON CORPORATION

FILE 'EMBAL' ENTERED AT 12:49:30 ON 28 APR 2005
COPYRIGHT (C) 2005 Elsevier Inc. All rights reserved.

FILE 'EMBASE' ENTERED AT 12:49:30 ON 28 APR 2005
COPYRIGHT (C) 2005 Elsevier Inc. All rights reserved.

FILE 'ESBIOBASE' ENTERED AT 12:49:30 ON 28 APR 2005
COPYRIGHT (C) 2005 Elsevier Science B.V., Amsterdam. All rights reserved.

FILE 'IFIPAT' ENTERED AT 12:49:30 ON 28 APR 2005
COPYRIGHT (C) 2005 IFI CLAIMS(R) Patent Services (IFI)

FILE 'IMSDRUGNEWS' ENTERED AT 12:49:30 ON 28 APR 2005
COPYRIGHT (C) 2005 IMSWORLD Publications Ltd

FILE 'IMSPRODUCT' ENTERED AT 12:49:30 ON 28 APR 2005
COPYRIGHT (C) 2005 IMSWORLD Publications Ltd

FILE 'IPA' ENTERED AT 12:49:30 ON 28 APR 2005
Copyright (c) 2005 The Thomson Corporation

FILE 'JICST-EPLUS' ENTERED AT 12:49:30 ON 28 APR 2005
COPYRIGHT (C) 2005 Japan Science and Technology Agency (JST)

FILE 'KOSMET' ENTERED AT 12:49:30 ON 28 APR 2005
COPYRIGHT (C) 2005 International Federation of the Societies of Cosmetics Chemists

FILE 'LIFESCI' ENTERED AT 12:49:30 ON 28 APR 2005
COPYRIGHT (C) 2005 Cambridge Scientific Abstracts (CSA)

FILE 'MEDICONF' ENTERED AT 12:49:30 ON 28 APR 2005
COPYRIGHT (c) 2005 FAIRBASE Datenbank GmbH, Hannover, Germany

FILE 'MEDLINE' ENTERED AT 12:49:30 ON 28 APR 2005

FILE 'NAPRALERT' ENTERED AT 12:49:30 ON 28 APR 2005
COPYRIGHT (C) 2005 Board of Trustees of the University of Illinois,
University of Illinois at Chicago.

FILE 'NLDB' ENTERED AT 12:49:30 ON 28 APR 2005
COPYRIGHT (C) 2005 Gale Group. All rights reserved.

FILE 'NUTRACEUT' ENTERED AT 12:49:30 ON 28 APR 2005
Copyright 2005 (c) MARKETLETTER Publications Ltd. All rights reserved.

FILE 'PASCAL' ENTERED AT 12:49:30 ON 28 APR 2005
Any reproduction or dissemination in part or in full,
by means of any process and on any support whatsoever
is prohibited without the prior written agreement of INIST-CNRS.
COPYRIGHT (C) 2005 INIST-CNRS. All rights reserved.

FILE 'PCTGEN' ENTERED AT 12:49:30 ON 28 APR 2005
COPYRIGHT (C) 2005 WIPO

FILE 'PHARMAML' ENTERED AT 12:49:30 ON 28 APR 2005
Copyright 2005 (c) MARKETLETTER Publications Ltd. All rights reserved.

FILE 'PHIC' ENTERED AT 12:49:30 ON 28 APR 2005
COPYRIGHT (C) 2005 T&F Informa UK Ltd.

FILE 'PHIN' ENTERED AT 12:49:30 ON 28 APR 2005
COPYRIGHT (C) 2005 T&F Informa UK Ltd.

FILE 'SCISEARCH' ENTERED AT 12:49:30 ON 28 APR 2005
Copyright (c) 2005 The Thomson Corporation

FILE 'TOXCENTER' ENTERED AT 12:49:30 ON 28 APR 2005
COPYRIGHT (C) 2005 ACS

FILE 'USPATFULL' ENTERED AT 12:49:30 ON 28 APR 2005
CA INDEXING COPYRIGHT (C) 2005 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'USPAT2' ENTERED AT 12:49:30 ON 28 APR 2005
CA INDEXING COPYRIGHT (C) 2005 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'AGRICOLA' ENTERED AT 12:49:30 ON 28 APR 2005

FILE 'ANABSTR' ENTERED AT 12:49:30 ON 28 APR 2005
COPYRIGHT (c) 2005 THE ROYAL SOCIETY OF CHEMISTRY (RSC)

FILE 'ANTE' ENTERED AT 12:49:30 ON 28 APR 2005
COPYRIGHT (C) 2005 Cambridge Scientific Abstracts (CSA)

FILE 'AQUALINE' ENTERED AT 12:49:30 ON 28 APR 2005
COPYRIGHT (C) 2005 Cambridge Scientific Abstracts (CSA)

FILE 'AQUASCI' ENTERED AT 12:49:30 ON 28 APR 2005
COPYRIGHT 2005 FAO (On behalf of the ASFA Advisory Board). All rights reserved.

FILE 'BIOBUSINESS' ENTERED AT 12:49:30 ON 28 APR 2005
Copyright (c) 1998 The Thomson Corporation.

FILE 'BIOCOMMERCE' ENTERED AT 12:49:30 ON 28 APR 2005
COPYRIGHT (C) 2005 BioCommerce Data Ltd. Richmond Surrey, United Kingdom. All rights reserved

FILE 'BIOENG' ENTERED AT 12:49:30 ON 28 APR 2005
COPYRIGHT (C) 2005 Cambridge Scientific Abstracts (CSA)

FILE 'BIOTECHABS' ACCESS NOT AUTHORIZED

FILE 'BIOTECHDS' ENTERED AT 12:49:30 ON 28 APR 2005
COPYRIGHT (C) 2005 THE THOMSON CORPORATION

FILE 'CABA' ENTERED AT 12:49:30 ON 28 APR 2005
COPYRIGHT (C) 2005 CAB INTERNATIONAL (CABI)

FILE 'CEABA-VTB' ENTERED AT 12:49:30 ON 28 APR 2005
COPYRIGHT (c) 2005 DECHEMA eV

FILE 'CIN' ENTERED AT 12:49:30 ON 28 APR 2005
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2005 American Chemical Society (ACS)

FILE 'CONFSCI' ENTERED AT 12:49:30 ON 28 APR 2005
COPYRIGHT (C) 2005 Cambridge Scientific Abstracts (CSA)

FILE 'CROPB' ENTERED AT 12:49:30 ON 28 APR 2005
COPYRIGHT (C) 2005 THE THOMSON CORPORATION

FILE 'CROPU' ENTERED AT 12:49:30 ON 28 APR 2005
COPYRIGHT (C) 2005 THE THOMSON CORPORATION

FILE 'FEDRIP' ENTERED AT 12:49:30 ON 28 APR 2005

FILE 'FOMAD' ENTERED AT 12:49:30 ON 28 APR 2005
COPYRIGHT (C) 2005 Leatherhead Food Research Association

FILE 'FOREGE' ENTERED AT 12:49:30 ON 28 APR 2005
COPYRIGHT (C) 2005 Leatherhead Food Research Association

FILE 'FROSTI' ENTERED AT 12:49:30 ON 28 APR 2005
COPYRIGHT (C) 2005 Leatherhead Food Research Association

FILE 'FSTA' ENTERED AT 12:49:30 ON 28 APR 2005
COPYRIGHT (C) 2005 International Food Information Service

FILE 'GENBANK' ENTERED AT 12:49:30 ON 28 APR 2005

FILE 'HEALSAFE' ENTERED AT 12:49:30 ON 28 APR 2005
COPYRIGHT (C) 2005 Cambridge Scientific Abstracts (CSA)

FILE 'IMSRESEARCH' ENTERED AT 12:49:30 ON 28 APR 2005
COPYRIGHT (C) 2005 IMSWORLD Publications Ltd

FILE 'NIOSHTIC' ENTERED AT 12:49:30 ON 28 APR 2005
COPYRIGHT (C) 2005 U.S. Secretary of Commerce on Behalf of the U.S. Government

FILE 'NTIS' ENTERED AT 12:49:30 ON 28 APR 2005

FILE 'OCEAN' ENTERED AT 12:49:30 ON 28 APR 2005

FILE 'PHAR' ENTERED AT 12:49:30 ON 28 APR 2005

FILE 'PROMT' ENTERED AT 12:49:30 ON 28 APR 2005

FILE 'PROUSDDR' ENTERED AT 12:49:30 ON 28 APR 2005

FILE 'PS' ENTERED AT 12:49:30 ON 28 APR 2005

FILE 'RDISCLOSURE' ENTERED AT 12:49:30 ON 28 APR 2005

FILE 'SYNTHLINE' ENTERED AT 12:49:30 ON 28 APR 2005

FILE 'VETB' ENTERED AT 12:49:30 ON 28 APR 2005

FILE 'VETU' ENTERED AT 12:49:30 ON 28 APR 2005

FILE 'WATER' ENTERED AT 12:49:30 ON 28 APR 2005

FILE 'WPIDS' ENTERED AT 12:49:30 ON 28 APR 2005

FILE 'WPIFV' ENTERED AT 12:49:30 ON 28 APR 2005

FILE 'WPINDEX' ACCESS NOT AUTHORIZED

=> s (hk2 or hGK(w) 2 or human (w) kallikrein (w) 2) and proteoly? and (pharmaceutical (w) composition or therapeutic (s) drug)

L1	0	FILE ADISCTI
L2	0	FILE ADISINSIGHT
L3	0	FILE ADISNEWS
L4	0	FILE BIOSIS
L5	0	FILE BIOTECHNO
L6	0	FILE CANCERLIT
L7	0	FILE CAPLUS
L8	0	FILE CEN
L9	0	FILE DDFB
L10	196	FILE DGENE
L11	0	FILE DISSABS
L12	0	FILE DRUGB
L13	0	FILE DRUGMONOG2
L14	0	FILE DRUGU
L15	0	FILE EMBAL
L16	0	FILE EMBASE
L17	0	FILE ESBIOBASE
L18	0	FILE IFIPAT
L19	0	FILE IMSDRUGNEWS
L20	0	FILE IMSPRODUCT
L21	0	FILE IPA
L22	0	FILE JICST-EPLUS
L23	0	FILE KOSMET

```
L24           0 FILE LIFESCI
L25           0 FILE MEDICONF
L26           0 FILE MEDLINE
L27           0 FILE NAPRALERT
L28           0 FILE NLDB
L29           0 FILE NUTRACEUT
L30           0 FILE PASCAL
L31           0 FILE PCTGEN
L32           0 FILE PHARMAML
L33           0 FILE PHIC
L34           0 FILE PHIN
L35           0 FILE SCISEARCH
L36           0 FILE TOXCENTER
L37          92 FILE USPATFULL
L38           5 FILE USPAT2
L39           0 FILE AGRICOLA
L40           0 FILE ANABSTR
L41           0 FILE ANTE
L42           0 FILE AQUALINE
L43           0 FILE AQUASCI
L44           0 FILE BIOBUSINESS
L45           0 FILE BIOCOMMERCE
L46           0 FILE BIOENG
L47           1 FILE BIOTECHDS
L48           0 FILE CABA
L49           0 FILE CEABA-VTB
L50           0 FILE CIN
L51           0 FILE CONFSCI
L52           0 FILE CROPB
L53           0 FILE CROPU
PROXIMITY OPERATOR LEVEL NOT CONSISTENT WITH
FIELD CODE - 'AND' OPERATOR ASSUMED 'ERAPEUTIC (S) DRUG'
L54           0 FILE FEDRIP
L55           0 FILE FOMAD
L56           0 FILE FOREGE
L57           0 FILE FROSTI
L58           0 FILE FSTA
L59           0 FILE GENBANK
L60           0 FILE HEALSAFE
L61           0 FILE IMSRESEARCH
L62           0 FILE NIOSHTIC
L63           0 FILE NTIS
L64           0 FILE OCEAN
L65           0 FILE PHAR
L66           0 FILE PROMT
L67           0 FILE PROUSDDR
L68           0 FILE PS
L69           0 FILE RDISCLOSURE
L70           0 FILE SYNTHLINE
L71           0 FILE VETB
L72           0 FILE VETU
L73           0 FILE WATER
L74           3 FILE WPIDS
L75           0 FILE WPIFV

TOTAL FOR ALL FILES
L76         297 (HK2 OR HGK(W) 2 OR HUMAN (W) KALLIKREIN (W) 2) AND PROTEOLY?
                AND (PHARMACEUTICAL (W) COMPOSITION OR THERAPEUTIC (S) DRUG)

=> s (hk2 or  hGK(w) 2  or human (w) kallikrein (w) 2) (s0 proteoly? and (pharmaceutical (w)
composition or therapeutic (s) drug)
MISSING OPERATOR 2) (S0
The search profile that was entered contains terms or
nested terms that are not separated by a logical operator.

=> s (hk2 or  hGK(w) 2  or human (w) kallikrein (w) 2) (s) proteoly? and (pharmaceutical (w)
composition or therapeutic (s) drug)
L77           0 FILE ADISCTI
```

```
L78           0 FILE ADISINSIGHT
L79           0 FILE ADISNEWS
L80           0 FILE BIOSIS
L81           0 FILE BIOTECHNO
L82           0 FILE CANCERLIT
L83           0 FILE CAPLUS
L84           0 FILE CEN
L85           0 FILE DDFB
L86         196 FILE DGENE
L87           0 FILE DISSABS
L88           0 FILE DRUGB
L89           0 FILE DRUGMONOG2
L90           0 FILE DRUGU
L91           0 FILE EMBAL
L92           0 FILE EMBASE
L93           0 FILE ESBIOBASE
L94           0 FILE IFIPAT
L95           0 FILE IMSDRUGNEWS
L96           0 FILE IMSPRODUCT
L97           0 FILE IPA
L98           0 FILE JICST-EPLUS
L99           0 FILE KOSMET
L100          0 FILE LIFESCI
L101          0 FILE MEDICONF
L102          0 FILE MEDLINE
L103          0 FILE NAPRALERT
L104          0 FILE NLDB
L105          0 FILE NUTRACEUT
L106          0 FILE PASCAL
L107          0 FILE PCTGEN
L108          0 FILE PHARMAML
L109          0 FILE PHIC
L110          0 FILE PHIN
L111          0 FILE SCISEARCH
L112          0 FILE TOXCENTER
L113          6 FILE USPATFULL
L114          0 FILE USPAT2
L115          0 FILE AGRICOLA
L116          0 FILE ANABSTR
L117          0 FILE ANTE
L118          0 FILE AQUALINE
L119          0 FILE AQUASCI
L120          0 FILE BIOBUSINESS
L121          0 FILE BIOCOMMERCE
L122          0 FILE BIOENG
L123          1 FILE BIOTECHDS
L124          0 FILE CABA
L125          0 FILE CEABA-VTB
L126          0 FILE CIN
L127          0 FILE CONFSCI
L128          0 FILE CROPB
L129          0 FILE CROPU
PROXIMITY OPERATOR LEVEL NOT CONSISTENT WITH
FIELD CODE - 'AND' OPERATOR ASSUMED '2) (S) PROTEOLY?'
PROXIMITY OPERATOR LEVEL NOT CONSISTENT WITH
FIELD CODE - 'AND' OPERATOR ASSUMED 'ERAPEUTIC (S) DRUG'
L130          0 FILE FEDRIP
L131          0 FILE FOMAD
L132          0 FILE FOREGE
L133          0 FILE FROSTI
L134          0 FILE FSTA
L135          0 FILE GENBANK
L136          0 FILE HEALSAFE
L137          0 FILE IMSRESEARCH
L138          0 FILE NIOSHTIC
L139          0 FILE NTIS
L140          0 FILE OCEAN
L141          0 FILE PHAR
```

```
L142          0 FILE PROMT
L143          0 FILE PROUSDDR
L144          0 FILE PS
L145          0 FILE RDISCLOSURE
L146          0 FILE SYNTHLINE
L147          0 FILE VETB
L148          0 FILE VETU
L149          0 FILE WATER
L150          3 FILE WPIDS
L151          0 FILE WPIFV

TOTAL FOR ALL FILES
L152        206 (HK2 OR HGK(W) 2 OR HUMAN (W) KALLIKREIN (W) 2) (S) PROTEOLY?
                AND (PHARMACEUTICAL (W) COMPOSITION OR THERAPEUTIC (S) DRUG)

=> dup rem l152
DUPLICATE IS NOT AVAILABLE IN 'ADISINSIGHT, ADISNEWS, DGENE, DRUGMONOG2,
IMSPRODUCT, KOSMET, MEDICONF, NUTRACEUT, PCTGEN, PHARMAML, BIOCOMMERCE,
FEDRIP, FOREGE, GENBANK, IMSRESEARCH, PHAR, PROUSDDR, PS, RDISCLOSURE,
SYNTHLINE'.
ANSWERS FROM THESE FILES WILL BE CONSIDERED UNIQUE
PROCESSING COMPLETED FOR L152
L153         205 DUP REM L152 (1 DUPLICATE REMOVED)

=> L152 and therapeutic (w) drug
L152 IS NOT A RECOGNIZED COMMAND
The previous command name entered was not recognized by the system.
For a list of commands available to you in the current file, enter
"HELP COMMANDS" at an arrow prompt (=>).

=>
<------User Break------>

=> s L152 and therapeutic (w) drug
L154          0 FILE ADISCTI
L155          0 FILE ADISINSIGHT
L156          0 FILE ADISNEWS
L157          0 FILE BIOSIS
L158          0 FILE BIOTECHNO
L159          0 FILE CANCERLIT
L160          0 FILE CAPLUS
L161          0 FILE CEN
L162          0 FILE DDFB
L163          0 FILE DGENE
L164          0 FILE DISSABS
L165          0 FILE DRUGB
L166          0 FILE DRUGMONOG2
L167          0 FILE DRUGU
L168          0 FILE EMBAL
L169          0 FILE EMBASE
L170          0 FILE ESBIOBASE
L171          0 FILE IFIPAT
L172          0 FILE IMSDRUGNEWS
L173          0 FILE IMSPRODUCT
L174          0 FILE IPA
L175          0 FILE JICST-EPLUS
L176          0 FILE KOSMET
L177          0 FILE LIFESCI
L178          0 FILE MEDICONF
L179          0 FILE MEDLINE
L180          0 FILE NAPRALERT
L181          0 FILE NLDB
L182          0 FILE NUTRACEUT
L183          0 FILE PASCAL
L184          0 FILE PCTGEN
L185          0 FILE PHARMAML
L186          0 FILE PHIC
L187          0 FILE PHIN
```

```
L188          0 FILE SCISEARCH
L189          0 FILE TOXCENTER
L190          1 FILE USPATFULL
L191          0 FILE USPAT2
L192          0 FILE AGRICOLA
L193          0 FILE ANABSTR
L194          0 FILE ANTE
L195          0 FILE AQUALINE
L196          0 FILE AQUASCI
L197          0 FILE BIOBUSINESS
L198          0 FILE BIOCOMMERCE
L199          0 FILE BIOENG
L200          0 FILE BIOTECHDS
L201          0 FILE CABA
L202          0 FILE CEABA-VTB
L203          0 FILE CIN
L204          0 FILE CONFSCI
L205          0 FILE CROPB
L206          0 FILE CROPU
L207          0 FILE FEDRIP
L208          0 FILE FOMAD
L209          0 FILE FOREGE
L210          0 FILE FROSTI
L211          0 FILE FSTA
L212          0 FILE GENBANK
L213          0 FILE HEALSAFE
L214          0 FILE IMSRESEARCH
L215          0 FILE NIOSHTIC
L216          0 FILE NTIS
L217          0 FILE OCEAN
L218          0 FILE PHAR
L219          0 FILE PROMT
L220          0 FILE PROUSDDR
L221          0 FILE PS
L222          0 FILE RDISCLOSURE
L223          0 FILE SYNTHLINE
L224          0 FILE VETB
L225          0 FILE VETU
L226          0 FILE WATER
L227          2 FILE WPIDS
L228          0 FILE WPIFV

TOTAL FOR ALL FILES
L229          3 L152 AND THERAPEUTIC (W) DRUG

=> d l299 ibib bas
L299 NOT FOUND
The L-number entered has not been defined in this session, or it
has been deleted.  To see the L-numbers currently defined in this
session, enter DISPLAY HISTORY at an arrow prompt (=>).

=> d 229 ibib abs
      3 ANSWERS ARE AVAILABLE.  SPECIFIED ANSWER NUMBER EXCEEDS ANSWER SET SIZE
The answer numbers requested are not in the answer set.
ENTER ANSWER NUMBER OR RANGE (1):l229
ANSWER NUMBERS NOT CORRECTLY SPECIFIED
Enter an answer number,       Example: 10
several answer numbers,       Example: 3,7,10
a range of answer numbers,    Example: 5-10
or a combination of these.    Example: 3,7,9-10,15
ENTER ANSWER NUMBER OR RANGE (1):
<------User Break------>

ENTER ANSWER NUMBER OR RANGE (1):
ENTER ANSWER NUMBER OR RANGE (1):L229
ANSWER NUMBERS NOT CORRECTLY SPECIFIED
Enter an answer number,       Example: 10
several answer numbers,       Example: 3,7,10
```

a range of answer numbers, Example: 5-10
or a combination of these. Example: 3,7,9-10,15
ENTER ANSWER NUMBER OR RANGE (1):1-3

L229 ANSWER 1 OF 3 USPATFULL on STN
ACCESSION NUMBER: 2003:96170 USPATFULL
TITLE: Tissue specific prodrug
INVENTOR(S): Isaacs, John T., Pheonix, MD, United States
Denmeade, Samuel R., Ellicott City, MD, United States
Christensen, S. Brogger, Nivaa, DENMARK
PATENT ASSIGNEE(S): The Johns Hopkins University, Baltimore, MD, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6545131	B1	20030408
APPLICATION INFO.:	US 2000-627851		20000728 (9)

RELATED APPLN. INFO.: Continuation-in-part of Ser. No. US 2000-588822, filed on 7 Jun 2000 Division of Ser. No. US 1998-81707, filed on 19 May 1998, now patented, Pat. No. US 6265540

	NUMBER	DATE
PRIORITY INFORMATION:	US 1998-80046P	19980330 (60)
	US 1997-47070P	19970519 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: GRANTED
PRIMARY EXAMINER: Huff, Sheela
LEGAL REPRESENTATIVE: Corless, Peter F., Rees, Dianne M., Edwards & Angell, LLP
NUMBER OF CLAIMS: 21
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 13 Drawing Figure(s); 13 Drawing Page(s)
LINE COUNT: 1997
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The invention provides novel peptide prodrugs which contain cleavage sites specifically cleaved by prostate specific antigen (PSA). These prodrugs are useful for substantially inhibiting the non-specific toxicity of a variety of **therapeutic drugs**. PSA is secreted by prostatic glandular cells. Upon cleavage of the prodrug by PSA, the **therapeutic drugs** are activated and exert their toxicity. Novel sesquiterpene-γ-lactones are also provided by the invention, and are designed to be linked to carrier moieties such as the peptides of the invention. Methods for treating cell proliferative disorders are also featured in the invention.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L229 ANSWER 2 OF 3 WPIDS COPYRIGHT 2005 THE THOMSON CORP on STN
ACCESSION NUMBER: 2004-460495 [43] WPIDS
DOC. NO. CPI: C2004-171852
TITLE: Novel peptide comprising a cleavage site specific for an enzyme having **proteolytic** activity of **human kallikrein 2**, useful for producing prodrugs for treating **human kallikrein 2**-producing cell proliferative disorders.
DERWENT CLASS: A96 B04 D16
INVENTOR(S): DENMEADE, S R; ISAACS, J T; LILJA, H
PATENT ASSIGNEE(S): (UYJO) UNIV JOHNS HOPKINS
COUNTRY COUNT: 106
PATENT INFORMATION:

PATENT NO	KIND	DATE	WEEK	LA	PG
WO 2004046169	A2	20040603	(200443)*	EN	48

RW: AT BE BG BW CH CY CZ DE DK EA EE ES FI FR GB GH GM GR HU IE IT KE LS LU MC MW MZ NL OA PT RO SD SE SI SK SL SZ TR TZ UG ZM ZW

W: AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK
DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR
KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PG PH
PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC
VN YU ZA ZM ZW

AU 2003291071 A1 20040615 (200470)

APPLICATION DETAILS:

PATENT NO	KIND	APPLICATION	DATE
WO 2004046169	A2	WO 2003-US36880	20031118
AU 2003291071	A1	AU 2003-291071	20031118

FILING DETAILS:

PATENT NO	KIND	PATENT NO
AU 2003291071	A1 Based on	WO 2004046169

PRIORITY APPLN. INFO: US 2002-427309P 20021118

AN 2004-460495 [43] WPIDS

AB WO2004046169 A UPAB: 20040709

NOVELTY - A peptide comprising an amino acid sequence having a cleavage site specific for an enzyme having a **proteolytic** activity of **human kallikrein 2 (hK2)**, is new.

DETAILED DESCRIPTION - A peptide (I) comprising an amino acid sequence (A1), having a cleavage site specific for an enzyme having a **proteolytic** activity of **human kallikrein 2 (hK2)**.

Gly-Lys-Ala-X1-X2-X3 (A1)

at least one of X1, X2, and X3 = arginine; and

the other two amino acid residues at X1, X2, and X3 = any amino acid.

INDEPENDENT CLAIMS are also included for:

(1) a peptide composition (II) comprising several (I);

(2) a polynucleotide (III) encoding (I); and

(3) a composition (IV) comprising a prodrug, which contains a therapeutically active **drug**, and (I), where the peptide is linked to the therapeutically active **drug** to inhibit the **therapeutic** activity of the **drug** and the therapeutically active **drug** is cleaved from the peptide upon **proteolysis** by an enzyme having a **proteolytic** activity of **hK2**.

ACTIVITY - Cytotoxic.

No biological data given.

MECHANISM OF ACTION - None given.

USE - (I) is useful for producing a prodrug, which involves linking a therapeutically active **drug** and (I), where the linking of the peptide to the **drug** inhibits the **therapeutic** activity of the **drug**. The therapeutically active **drug** has a primary amine and the prodrug contains a liner between the peptide and the **drug**, where the linker comprises preferably leucine. (I) is useful for detecting hK2-producing tissue, which involves contacting the tissue with composition comprising a detectable labeled (I) for a period of time sufficient to allow cleavage, and detecting the detectable label, where the detectable label is a fluorescent label, radioactive label, chromophoric label or chemiluminescent label. The fluorescent label is chosen from 7-amino-4-methyl coumarin, 7-amino-4-trifluoromethyl coumarin, rhodamine 110, and 6-aminoquinoline. The radioactive label is chosen from tritium, carbon-14, and iodine-125. (I) is useful for selecting a hK2 activatable prodrug, where the prodrug is substantially specific for target tissue comprising hK2-producing cells, which involves linking (I), to a **therapeutic drug** to produce a peptide-**drug** composition, contacting the composition with cells of the target tissue, contacting the composition with cells of a non-target tissue, and selecting complexes that are substantially toxic towards target tissue cells, but which are not substantially toxic towards non-target tissue cells. (I) is useful for determining the activity of hK2 in a sample containing hK2, which involves contacting the sample with a

composition comprising a detectably labeled (I) for a period of time sufficient to allow cleavage of the peptide, detecting the detectable label to yield a detection level, comparing the detection level with a detection level obtained from contacting the detectably labeled peptide with a standard hK2 sample. (I) is useful for imaging hK2-producing tissue, which involves administering (I) linked to a lipophilic imaging label to a subject having or suspected of having an hK2 producing associated cell-proliferative disorder, allowing a sufficient period of time to pass to allow cleavage of the peptide by hK2 and to allow clearance of uncleaved peptide from the subject to provide a reliable imaging of the imaging label and imaging the subject. (I) is useful for identifying a peptide sequence which can be a substrate for hK2 comprising incubating a random peptide library, which involves the peptides, with hK2, detecting (I) which is cleaved by hK2, and determining the sequence of the cleaved peptide, where the peptides comprising a label which is detectable only after cleavage by hK2. (IV) is useful for treating an hK2-producing cell proliferative disorder, which involves administering (IV) to a subject having the cell proliferative disorder, where the disorder is benign or malignant such as prostate cancer, breast cancer (claimed).

ADVANTAGE - (I) is efficiently and specifically cleaved by hK2. (IV) is highly stable in human and mouse plasma and do not show significant non-specific toxicity.

DESCRIPTION OF DRAWING(S) - The figure shows a graph representing a human glandular kallikrein (hK2) mediated hydrolysis of various peptide and prodrug substrates.

Dwg.8/9

L229 ANSWER 3 OF 3 WPIDS COPYRIGHT 2005 THE THOMSON CORP on STN

ACCESSION NUMBER: 2001-191450 [19] WPIDS

DOC. NO. CPI: C2001-057354

TITLE: New peptides containing cleavage sites specifically cleaved by human kallikrein 2, useful for producing prodrugs which treat hK2-producing cell proliferative disorders without exhibiting non-specific toxicity.

DERWENT CLASS: B04 D16

INVENTOR(S): CHRISTENSEN, S B; DENMEADE, S R; ISAACS, J T; LILJA, H

PATENT ASSIGNEE(S): (UYJO) UNIV JOHNS HOPKINS

COUNTRY COUNT: 94

PATENT INFORMATION:

PATENT NO	KIND	DATE	WEEK	LA	PG
WO 2001009165	A2	20010208	(200119)*	EN	38

RW: AT BE CH CY DE DK EA ES FI FR GB GH GM GR IE IT KE LS LU MC MW MZ NL OA PT SD SE SL SZ TZ UG ZW

W: AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG UZ VN YU ZA ZW

AU 2000076272	A	20010219	(200129)		
EP 1274723	A2	20030115	(200306)	EN	

R: AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

APPLICATION DETAILS:

PATENT NO	KIND	APPLICATION	DATE
WO 2001009165	A2	WO 2000-US40496	20000728
AU 2000076272	A	AU 2000-76272	20000728
EP 1274723	A2	EP 2000-965573	20000728
		WO 2000-US40496	20000728

FILING DETAILS:

PATENT NO	KIND		PATENT NO
AU 2000076272	A	Based on	WO 2001009165

EP 1274723 A2 Based on WO 2001009165

PRIORITY APPLN. INFO: US 1999-146316P 19990729
AN 2001-191450 [19] WPIDS
AB WO 200109165 A UPAB: 20010405
NOVELTY - A peptide (I) comprising an amino acid sequence having a cleavage site specific for an enzyme having a **proteolytic** activity of **human kallikrein 2 (hK2**), and which is upto 20 amino acids in length, is new.

DETAILED DESCRIPTION - INDEPENDENT CLAIMS are also included for the following:

(1) a peptide composition (II) comprising several (I);

(2) a polynucleotide (III) encoding (I) and

(3) a composition (IV) comprising a prodrug which comprises a therapeutically active **drug** and (I), in which (I) is linked to the **drug** to inhibit its **therapeutic** activity and in which the **drug** is cleaved upon **proteolysis** by an enzyme having a **proteolytic** activity of **hK2**.

ACTIVITY - Cytostatic.

No biological data is given.

MECHANISM OF ACTION - Prodrugs.

USE - (I) is useful for producing a prodrug which involves linking a **drug** which contains a primary amine to (I), in which the linking of the peptide to the **drug** inhibits the **therapeutic** activity of the **drug**. The prodrug produced contains a linker (amino acid, leucine) between (I) and the **drug**. (IV) is useful for treating hK2 producing-cell proliferative disorder such as benign or malignant prostate cancer or breast cancer. (I) Is also useful for detecting human kallikrein 2-producing tissue, which involves contacting the tissue with a composition comprising a detectably labeled-(I) to allow cleavage of (I) and then detecting the detectable label. The (I) used in the method comprises a capping group attached to the N-terminus of the peptide. (I) is labeled with a radioactive label such as tritium, carbon-14 or iodine-125 or the detectable label is a chromophoric label or a chemiluminescent label. (I) is useful for selecting a hK2 activatable prodrug specific for a target tissue comprising hK2-producing cells which involves linking (I) to a **drug** to produce a peptide-**drug** composition which is contacted with the cells of the target tissue and with cells of a non-target tissue, after which complexes that are substantially toxic towards target tissue cells, but which are not toxic towards non-target tissue cells, are selected.

(I) Is useful for determining the activity of a hK2 in a sample containing hK2 which involves contacting the sample with a composition comprising detectably labeled (I) to allow cleavage of the peptide, detecting the detectable label to yield a detection level and then comparing the detection level obtained from contacting the detectably labeled peptide with a standard hK2 sample. (I) Is also useful for imaging hK2-producing tissue which involves administering a peptide linked to a lipophilic imaging label to a subject having or suspected of having a hK2 producing associated cell-proliferative disorder, allowing cleavage of the peptide and clearance of the uncleaved peptide from the subject to provide a reliable imaging of the imaging level and imaging.

ADVANTAGE - The coupling of (I) to a cytotoxic drug creates an inactive prodrug that can only become activated at sites where enzymatically active hK2 is produced.

Dwg.0/0

=>